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ABSTRACT 
Type 1 Diabetes Mellitus (T1D) is a common form of Diabetes Mellitus worldwide and 
can cause long-term complications, especially in children.  Diabetic nephropathy (DN) is the 
leading cause of mortality in T1D. The non-invasive gold standard for screening, monitoring, 
and predicting progression of DN is the assessment of albuminuria. However, it has been shown 
to lack sensitivity and specificity for early pathological manifestations of the disease. Other 
biomarkers including α-klotho, serum uric acid and estimated glomerular filtration rate (GFR) 
might potentially have a better ability to detect onset of DN earlier. The goal of this study is to 
gain a better understanding of how these biomarkers are associated with demographic and 
clinical characteristics in children.  
Data from 97 children, age 10 or more years with a T1D duration of at least 2 years, were 
collected at Children’s Hospital of Pittsburgh over a 4 month period. Correlations and 
univariable regression models were built to detect whether significant relationships between 
these biomarkers and demographic and clinical predictors were present. Multivariate regression 
models for each of the biomarkers were constructed and the cross-validation method was used to 
validate the models. After selecting the final models, linear regression assumptions were checked 
and model diagnostics were performed to detect problematic data points. 
The final model for α-klotho contained the variables of hemoglobin A1c, growth 
velocity, triglycerides, total cholesterol, HDL and central obesity. For estimated GFR, the model 
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included hemoglobin A1c, diastolic blood pressure percentile, growth velocity, albumin 
creatinine ratio (ACR), creatinine, total cholesterol and central obesity. The final model for 
serum uric acid included hemoglobin A1c, diabetic duration years, age, ACR, creatinine, 
triglycerides, total cholesterol, HDL, central obesity and waist percentile. Model fit criteria for 
all three multivariate models were largely improved compared to univariable models. Model 
diagnostics showed few problematic data points and linear regression assumptions for all three 
best models were not violated. 
Public Health Significance: Although these biomarkers have been studied in adults with 
respect to screening, monitoring, and predicting progression of DN, less work has been done in 
pediatric populations. The work here provides a better understanding of the relationship between 
these biomarkers, and the demographic and clinical characteristics of children with T1D. The 
regression model validation techniques employed provide models that are not overly optimistic 
with respect to prediction. These methods are also more appropriate for studies with smaller 
sample sizes as found in this study.  
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1.0  INTRODUCTION 
1.1 TYPE 1 DIABETES MELLITUS 
Diabetes Mellitus is a chronic disease which is caused by low insulin production level causing 
high blood sugar levels. Symptoms of Diabetes Mellitus include increased urination, increased 
hunger, increased thirst, and decreased weight. Diabetes Mellitus is the seventh most common 
disease both in the United States and in the world [1]. Currently, 29.1 million people in the 
United State have Diabetes Mellitus. That is 1 out of 11 people. The risk of death for adults with 
Diabetes Mellitus is 50% higher than in adults without Diabetes Mellitus [2]. Diabetes Mellitus 
can also cause many complications, including blindness, kidney diseases, heart attack and stroke 
[3]. T1D is a very common type of Diabetes Mellitus in the world. 5%-10% of the total cases of 
Diabetes Mellitus worldwide are T1D patients [4]. Currently, the incidence rate of T1D increases 
by about 3% per year [5]. 
Type 1 Diabetes Mellitus (T1D) is a type of autoimmune disease caused by genetic defect 
and environmental factors and may result in the destruction of beta cells. T1D occurs when the 
body cannot produce enough insulin and may develop for people at any age. Generally, children 
or young adults are at a high risk for T1D [2]. People with Type I Diabetes Mellitus usually 
depend on exogenous insulin throughout their remaining lifetime [6]. Currently, there is no 
known method to prevent and cure Type I Diabetes Mellitus The mechanism and pathology of 
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Type I Diabetes Mellitus is a hot research topic [9]. As a result, we need to pay more attention to 
the prevention and diagnosis of T1D. 
1.2 DIABETIC NEPHROPATHY 
Diabetic nephropathy (DN) is defined as persistent proteinuria > 500mg/24h or albuminuria > 
300mg/24h [10]. Diabetic nephropathy is the leading cause of mortality in Type I Diabetes 
Mellitus [11]. According to the Finnish Diabetic Nephropathy Study, individuals who had T1D 
but without DN had an equivalent mortality compared to the general Finnish population. In 
contrast, individuals who had T1D and DN have much higher mortality compared to the general 
Finnish population [12]. Hence, it is very important to emphasize the need for prevention and 
early identification of DN. Recent screening guidelines from the International Society for 
Pediatric and Adolescent Diabetes (ISPAD) suggest that youth with T1D should be screened for 
DN from age 10 with 2-5 years of diabetic duration years. If puberty onset occurs earlier than 
age 10, young children should be screened at the onset of puberty. Screening should be 
performed annually [13]. Currently, albuminuria is the gold standard for screening and predicting 
the progression of DN in children with T1D [14]. However, it has been shown that the gold 
standard method lacked sensitivity for early pathological manifestations of the disease [15]. 
Therefore, we need to identify potential biomarkers that relate to DN or diabetic control. The 
assessment of potential biomarkers can be evaluated by constructing appropriate statistical 
models. Estimated GFR, α-klotho and serum uric acid (SUA) were selected to study novel 
biomarkers based on previous work and literature review. 
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1.3 ALPHA-KLOTHO  
Klotho is a type of protein which is responsible for transporting organism to insulin. Alpha-
klotho (α-klotho) is found in the human body as a necessary co-receptor molecule for the FGF23 
function and is important for phosphate handling and calcitriol regulation at the kidney level 
[16]. The soluble form of α-klotho is derived from a cleavage of an extracellular portion of the 
transmembrane α-klotho (renal α-klotho). Both renal and soluble forms of α-klotho have been 
found to have decreased expressions in chronic kidney disease and result in bone mineral 
abnormalities [17]. Recently, α-klotho was shown to have negative association with albuminuria 
[18]. It has also been shown to be correlated with Hemoglobin A1c [17]. However, to our 
knowledge, no study has examined the relationships between α-klotho and different demographic 
and clinical factors. 
1.4 ESTIMATED GFR 
Glomerular filtration rate (GFR) is often used to measure kidney function and estimated GFR 
(eGFR) can be obtained by using a Cystatin C-based equation [20]. A Number of formulas have 
been established to estimate GFR and many formulas base on the creatinine. In our study, 
Cystatin C-based equation was used because creatinine is not stable in the human body. Serum 
cystatin C is a more precise reflection of kidney function than serum creatinine levels. Renal 
hyperfiltration (assessed by GFR) may be the earliest abnormality of kidney function and it is 
associated with an increased risk of DN [21]. Also, serum Cystatin C is associated with insulin 
resistance in patients with type 1 diabetes, which may result in cells failing to respond normally 
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to the insulin [22]. Currently, to our knowledge, no study has examined the relationships 
between eGFR and different demographic and clinical predictors. 
1.5 SERUM URIC ACID 
Serum uric acid (SUA) predicts vascular complications in T1D and is considered one of the risk 
factors of T1D. It has been shown that patients with T1D have decreased SUA. In addition, some 
other evidence shows that SUA is associated with vascular complications in T1D [23][24]. So 
SUA was involved as a novel biomarker to predict DN among patients with T1D. Also, SUA has 
been shown to predict the development of albuminuria in adults with T1D [25] and it is 
associated with reduced insulin sensitivity [26]. To our knowledge, no study has examined the 
relationships between serum uric acid and different demographic and clinical predictors. 
1.6 GOALS 
The goal of this study is to assess whether potential risk biomarkers correlate with albuminuria 
as measured by Albumin/Creatinine Ratio (ACR), and glycemic control as measured by 
Hemoglobin A1c (HbA1c). Multivariate regression modeling techniques will be used to identify 
models for biomarkers that are not over-optimized. Appropriate variables will be selected from 
the candidate variables and will be used to predict the different risk biomarkers. Multiple 
regression modelling will be used to build models relating demographic and clinical factors to 
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these biomarkers. Various model selection procedures will be used to select the terms in the final 
models and the results compared among the candidate models. 
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2.0  METHODS 
2.1 STUDY DESIGN AND SUBJECTS 
This study is a pilot/exploratory study and includes data collected from100 children who 
satisfied ISPAD and ADA criteria for screening for complications in T1D. The criteria are: (1) at 
least 10 years old, and (2) have at least 2 years duration of Type I Diabetic.  Subjects were 
recruited from children who were seen at the Diabetes Center at the Children’s Hospital of 
Pittsburgh of UPMC between March 2016 to June 2016.  
Initial study data included information from available electronic medical records. These 
data included subjects’ demographical information such as age, gender, height and weight. Once 
eligible subjects were identified, the principle investigator contacted subjects/parents/guardian 
and asked them if they wanted to participate in the study. A total of 100 children with T1D were 
identified during the recruitment time period. A more detailed review of subjects’ characteristics 
related to T1D and DN identified three children ineligible for this study and were subsequently 
excluded. Thus, there were in total 97 subjects for the study.  
Informed consent was obtained for all subjects. This study was approved by the 
University of Pittsburgh and Children’s Hospital Institutional Review Board. 
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2.2 INDEPENDENT VARIABLES 
2.2.1 Demographic variables 
 Average systolic and diastolic blood pressure percentile 
High blood pressure was considered as one of the complications caused by Diabetes [9]. Systolic 
and diastolic blood pressure (SBP or DBP) were measured three times at the same clinic visit 
when patients came to Children’s Hospital. Average SBP or DBP were used to represent the 
corresponding blood pressure for the subject. It is typical to use BP percentile adjusted by age, 
gender and other variables instead of BP because BP percentile is more appropriate to represent 
BP characteristics and cause less bias than raw BP [27]. 
 BMI percentile 
Body Mass Index (BMI) was calculated as mass/height2 and the unit is kg/m2. It is widely used 
to represent the level of shape of the human body and adiposity. BMI percentile adjusting for 
age, race and gender is considered a more relevant measure than BMI when assessing children as 
it takes into account norms across demographics subgroups Subjects with higher BMI, usually 
greater than 85% BMI percentile, are recognized as overweight. Subjects whose BMI percentile 
are greater than 95% BMI percentile are recognized as obese. 
 Waist/height ratio and central obesity 
Waist/height ratio (WHR) is defined as the waist circumference divided by the height. It is 
universally used to reflect the body fat and obesity for a person. Central obesity is a dichotomous 
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variable of waist/height ratio [28]. In this study, WHR larger than 0.5 is considered to have a 
tendency of central obesity and more adverse health. 
 Waist circumference percentile 
Waist circumference is often used to assess the obesity level for a person. Waist circumference 
percentile adjusting for age, gender and race is considered more relevant than waist 
circumference to predict obesity or other disease because it can reflect the actual obesity level for 
children of different age levels, gender, and race [29]. 
2.2.2 Clinical variables 
 Hemoglobin A1c 
Hemoglobin A1c (HbA1c) measures plasma glucose concentration and generally it is used to 
represent the glycemic control level. It has been shown that HbA1c is related to Diabetes and 
cognition [30]. Hypoglycemia and Hyperglycemic crisis are two complications caused by 
Diabetes Mellitus [9]. Therefore, HbA1c would be included in the clinical variables to examine 
the relationships with risk biomarkers. 
 Albumin Creatinine Ratio 
Albumin Creatinine Ratio (ACR) is defined as the albumin divided by creatinine. ACR can 
reflect the albuminuria level, which is the non-invasive gold standard to predict the progression 
of DN. Also, it is an important index which can identify proteinuria and reflect the kidney 
function [31]. 
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 Triglycerides 
Triglyceride (TG) is one of the important substances which constitutes body fat [32]. 
Triglyceride level is considered important in predicting obesity among people. Higher 
Triglycerides usually represents higher body fat and thus a higher risk of obesity-related disease 
such as heart disease and Diabetes Mellitus [33]. 
 Total cholesterol 
Cholesterol is a type of sterol and it is one of the essential components of the cell membrane. The 
functions of Cholesterol are to build animal membranes and to synthesize steroid hormones. It is 
a risk factor of cardiovascular diseases and higher cholesterol represents a higher risk of 
cardiovascular diseases [34]. 
 HDL and LDL 
High-density lipoproteins (HDL) is one of five major lipoproteins. A low-level HDL is 
recognized as a risk factor of cardiovascular diseases and has close relationship with cholesterol 
[34].  Low-density lipoproteins (LDL) is also one of five major lipoproteins and it is well-known 
as a risk factor of cardiovascular diseases [35]. In addition, high blood LDL cholesterol is one of 
the complications caused by Diabetes Mellitus [9]. Hence, Cholesterol, HDL and LDL will be 
included in the model construction to see whether they are significant predictors for three novel 
biomarkers. 
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2.3 DATA MANAGEMENT 
All study data from the electronic medical records was entered into an Excel by the study 
investigator. Upon receiving the Excel file containing the raw data, I was responsible for all of 
the project data management and analysis. This included a comprehensive review of all raw data, 
cleaning of the dataset and performing all statistical analysis including modelling and graphical 
analysis.  
My initial step was to review the entire dataset for any errors, outliers and missing data 
that were not consistent with the data value specifications. This was followed by logic checks 
between variables within a subject. This included verifying that date sequences and combinations 
of variables made logical sense. All issues with the data were communicated to the study 
investigator and updated data files were obtained. For all transformed and calculated measures in 
the data set, I verified their accuracy. Prior to any analyses, I examined all variables for their 
distributional characteristics to assure that the statistical assumptions of the proposed analyses 
were met.  
2.4 STATISTICAL ANALYSIS 
The following parts are a brief description of correlation methods, model selection methods, 
model selection criteria, and problematic points methods. More details can be found in 
Regression analysis by Example, 5th edition [36]. 
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2.4.1 Correlation 
There are two types of correlations that are most commonly used: Pearson correlation and 
Spearman correlation. 
 
 Pearson correlation 
Pearson correlation coefficient is a parametric method to measure the linear correlation between 
two variables. Pearson correlation coefficient is calculated as the covariance of two variables 
divided by the standard deviation of each variable [35]. It ranges between -1 and 1. Pearson 
correlation coefficients equal to -1 or 1 indicate a perfect linear relationship between two 
variables. Usually, Pearson correlation is used when two variables are continuous and bivariate 
normally distributed. 
 Spearman correlation 
Spearman correlation coefficient is a nonparametric method to measure the rank of two 
variables. Spearman correlation evaluates whether the monotonic relationship exists between two 
variables. If Spearman correlation coefficient equals to -1 or 1, a perfect monotonic relationship 
is present for the two variables. Spearman correlation is appropriate for both normal or non-
normal data, continuous or order categorical variables.  
In our study, because some variables are not normally-distributed and ordered categorical 
variables are included, Spearman correlations were used to estimate associations between 
biomarkers and predictors. 
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2.4.2 Univariable regression 
Univariable regression is a regression method which only includes one regressor at a time. In our 
study, each variable was fitted in a univariable regression model for each potential biomarker. P-
values and R-square were displayed to show how well each univariable regression model 
performed. 
2.4.3 Multiple regression 
Multiple regression is an extension to the univariable regression model. A multiple regression 
model can include several independent variables in one model. A multiple regression model is 
usually a more precise model than a univariable model because it involves more predictors and 
can predict the outcome better. However, it is difficult to choose the best model and assess the 
overall fit of multiple regression model. Some model selection criteria and methods need to be 
assessed to evaluate the fit of multiple regression models. 
2.4.4 Model selection methods 
Generally, there are three types of model selection methods. They are: backwards elimination, 
forwards selection, and stepwise regression. 
 
 Backwards elimination 
Backwards elimination is one of the model selection methods which first includes all 
independent variables. Based on model selection criterion, the variable with the worst value of 
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selection criterion is removed from the model. Then the model is reestimated using remaining 
variables and then the second worst variable is removed. These steps are repeated until the 
stopping rule is reached and no other variable can be removed from the model. 
 
 Forwards selection 
Forwards selection is one of the model selection methods which starts the model with no 
predictors. Based on the model selection criterion, the first variable with the best value of 
selection criterion is added into the model. Then the second variable with the best value of 
selection criterion in the remaining variable list is added into the model. These steps are repeated 
until the stopping rule is reached and no other variables can be added into the model. 
 
 Stepwise regression 
Stepwise regression is a modified method of forwards selection or backwards elimination. It 
allows variables to enter and leave the model at each step. The model selection criterion is 
computed at each step of the forwards selection or backward elimination. The variable with the 
worst value of selection criterion is removed from the model and the model is refitted with the 
remaining variables. The iteration is repeated until the stopping rule is reached and no other 
variable can be added or removed from the model. 
In our study, the backwards elimination method was used instead of forwards selection 
because the maximum model could be constructed using backwards elimination. Moreover, 
backwards elimination can handle the collinearity issue better than forwards selection. 
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2.4.5 Model selection criteria 
There are many model selection criteria that are commonly used in the model selection. In our 
study, R-square or adjusted R-square, Akaike Information Criteria (AIC), Bayes Information 
Criteria (BIC), Mallow’s Cp, predicted residual error sum of squares (PRESS) or cross-
validation predicted residual error sum of squares (CV PRESS) were used as the model selection 
criteria. 
 
 R-square and adjusted R-square 
R-square is the squared multiple correlation coefficient. It can be interpreted as the proportion of 
variability of the dependent variable that can be explained by the predictive variables. The R-
square increases when more variables are added into the model. It will not decrease as the 
number of variables increase. Large R-square close to 1 indicates the model has a good fit.  
The adjusted R-square is an approach to solve the condition that R-square increases when 
other variables are added into the model and automatically increase R-square. This form of R-
square adjusts for the number of predictors and are always less than or equal to R-square. 
 
 Akaike Information Criteria (AIC) 
Akaike Information Criteria (AIC) is one of the model selection criteria which aims at balancing 
the accuracy of the model and the simplicity of the model. Usually with the increase of 
predictors, the model has a better fit and accuracy. However, overfitting may occur as the 
number of predictors increase. Thus, it is necessary to find a balance between accuracy and 
simplicity. The model with smaller AIC is preferred. Also, two models with the difference of 
AIC no more than 2 are considered equivalent.  
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 Bayes Information Criteria (BIC) 
Bayes Information Criteria (BIC) is the modified version of AIC. The difference between AIC 
and BIC is the severity of penalty for the number of predictors. The BIC method has a more 
severe penalty. As a result, the BIC method can better control the overfitting issue. The model 
with smaller BIC is preferred and the value of BIC is always less than AIC. 
 
 Mallow’s Cp 
Mallow’s Cp is one of the  model selection criteria used to estimate the standard total mean 
squared error of prediction. The expectation of Cp is the number of predictors p when the model 
is unbiased. Thus, the model with the value of Cp closed to the number of predictors is 
considered a good model. The model with a small value of Mallow’s Cp indicates a good 
precision in predicting the future outcomes. 
 
 Predicted residual error sum of squares (PRESS)  
Predicted residual error sum of squares (PRESS) is the sum of the residual square. It is used to 
assess the fit and accuracy of a model. PRESS can measure how well the model can predict for 
new observations [37]. Smaller PRESS values indicate better model structures. CV PRESS is the 
cross-validation predicted residual error sum of squares. The PRESS values are calculated in 
each step of cross-validation. 
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2.4.6 Model validation techniques 
After fitting the appropriate model, different model validation technique can be used to validate 
the model and test how well the model predicts for new observations. Different model validation 
techniques are described below: 
 
 Least Absolute Shrinkage and Selection Operator (LASSO) 
Least Absolute Shrinkage and Selection Operator (LASSO) is a type of least squares regression. 
LASSO finds the values of regression coefficients which minimize the mean residual sum of 
squares, where the sum of absolute values of coefficients is constrained to less than or equal to a 
constant t. Since the t is usually a small value, the regression coefficients are usually close to 
zero. LASSO can improve the accuracy of selected models and it can be used for many statistical 
models such as regression models, generalized linear models and proportional hazard models. 
However, since many coefficients are small and close to zero, sometimes it is hard to interpret 
the model using LASSO.  
 
 Bootstrapping 
Bootstrapping is a model validation technique which can be used to evaluate the models and 
parameter estimates without making assumptions for the distributions. It can be used when the 
sample size is small and overfitting issue exists. For bootstrapping, B repeated samples of size n 
are drawn with replacement. Then the analysis is repeated based on each of the B datasets. The 
parameter estimates are based on the average of the B bootstrap samples. It is easy to derive the 
point estimates and confidence interval of parameters using bootstrapping. However, although 
the bootstrapping can be used to small simple size, it could still cause some bias. 
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 Cross-validation 
Cross-validation is a model validation method to evaluate how well the predictive model 
performs and how well they can be applied to other observations [38]. If the whole dataset is 
used to construct the model and predict the outcomes, no other data would be used to examine 
how well the model will be predictive for new data,  
The common cross-validation method splits data into two parts: training set and testing 
set. Training set is used to fit the model and predict the outcomes, Testing set is used to test how 
well the predictive model performs for another dataset. 
Exhaustive and Non-exhaustive cross-validation are two categories of this method. 
Exhaustive cross-validation tests all possible ways for splitting the dataset. There are two major 
methods for exhaustive cross-validation: leave-one-out cross-validation and leave-p-out cross-
validation. 
Leave-p-out cross-validation puts p observations into the testing set and the remaining n-
p observations into the training set. Each combinations of p from the sample sizes n are chosen 
exactly one time as the testing set and this method chooses all possible combinations of p from n. 
As a result, this method is extremely time-consuming, especially when n is large. 
Leave-one-out cross-validation is a special case of leave-p-out cross-validation when p=1 
and it is similar to jackknifing. Each observation is chosen as the testing set for exactly one time 
so there are in total n possible combinations for the selection of testing set. This cross-validation 
method is not time-consuming for our study because the sample size of our study is relatively 
small. 
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Non-exhaustive cross-validation do not test all possible ways for splitting the dataset. 
There are many non-exhaustive cross-validation methods, which are introduced as follow. 
K-fold cross-validation is one commonly-used exhaustive cross-validation method. In 
this method, the dataset is partitioned into k subsets of equal size. Each subset is treated as the 
testing set for one time and the remaining k-1 subsets are treated as the training set. For example, 
if k=5, the original dataset is partitioned into 5 subgroups. At each time, 1 of 5 subgroups will be 
selected as the testing set and the other 4 groups will be the training set. The iterations will be 
repeated five times until each of five subgroups has been chosen to be the test set for exactly one 
time. Different k values will affect the results of cross-validation. If k=n, the n-fold cross-
validation is the same method as leave-one-out cross-validation. Hence, the choice of k is 
important and it should be assessed when we are doing the model selection. 
Hold out method is the simplest cross-validation method. It randomly splits the data into 
training set and testing set. But it runs just for a single time. This method lacks accuracy because 
it only uses one training set and one testing set to predict and validate the model. The results 
could be different based on the choice of training set and testing set. 
Monte Carlo cross-validation randomly splits the data into training set and testing set. 
The Monte Carlo cross-validation runs multiple time based on different splits, which can largely 
reduce the bias caused by choice of training set and testing set. However, some observations in 
the dataset may not be selected in the testing set even one time. Some observations could be 
selected in the testing set for more than one time. 
In our study, since we want each observation to be treated as the testing observation for 
one time and models that are easy to construct and interpret, we will use only k-fold cross-
validation methods as the model validation techniques based on different choice of k. 
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The feature of the study is to use k-fold cross-validation methods to choose appropriate 
models for the three potential biomarkers. CV PRESS is used as the selection rule in our study. 
Different model selection criteria are used to compare and select the final models for each choice 
of k. In addition, selection results for different choices of k for k-fold cross-validation are 
compared in order to select the best cross-validation method for three models. 
2.4.7 Problematic points checking 
There are many types of problematic points that are commonly checked after the construction of 
models. In our study, outliers, leverage, and influence were checked to see whether the model 
had any problematic points. 
 
 Outliers 
An Outlier is an observation which is far more different than other observations [39]. Outliers 
can be assessed by graphical residual analysis such as histogram, stem and leaf, box plot or 
scatter plot. In our study, scatter plots of studentized residuals were used to find outliers. Any 
values larger than ± 2 were considered an outlier, which correspond to approximately 5% of 
residuals when residuals were normally distributed. 
 
 Leverage 
In the multiple regression, assuming that the model is Y=Xβ + ε, X(X’X)-1X’ is called the Hat 
matrix. The ith diagonal element of the Hat matrix is called the leverage of ith observation. High 
leverage points usually represent that those points have undue influence on the model. In our 
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study, the scatter plots of studentized residuals versus leverage were used to find any high 
leverage points. 
 
 
 Influence 
Influence measures how much the regression coefficients change when ith observation is deleted 
from the model. If the deletion of ith observation causes a large change for the coefficients, that 
observation can be viewed as the influential point. There are many methods which can be used to 
detect the influential points. In our study, Cook’s Distance and DFFITS were used to find 
influential points. 
Cook’s Distance is a squared distance between estimated parameters for all the dataset 
and estimated parameters for the dataset when ith observation is dropped. Higher Cook’s 
Distance values indicate that the deletion of that observation may have a large influence on the 
regression coefficients. In our study, Cook’s Distance was assessed by a plot of Cook’s Distance 
versus the observation No. 
DFFITS is another way to detect the influential points. It also measures how much the 
regression coefficients change when ith observation is deleted from the model. It is similar with 
studentized residual. A high DFFITS value or a low DFFITS value indicates a high influential 
point. In our study, DFFITS was assessed by a plot of DFFITS versus the observation No. 
2.4.8 Software 
All parts of statistical analysis were done by using SAS 9.4 (SAS Institute, Cary, NC). 
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3.0  RESULTS 
3.1 DESCRIPTIVE CHARACTERISITICS 
3.1.1 Continuous variables 
The descriptive analysis of continuous variables was based on 97 eligible subjects and 17 
selected continuous variables (Table 1). The age of subjects was 15.8 ± 2.9 and ranged between 
10.0 and 23.6. The mean diabetic duration year was 7 years and ranged between 2.1 to 17.6. The 
median BMI percentile was 75.9% and larger than the mean BMI percentile (65.7%), which 
indicated that over half of the children were overweight. Other descriptive characteristics of 
continuous variables are shown in Table 1.  Table 1 also shows that there was missing data for 
several variables. 
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Table 1. Descriptive statistics for continuous variables 
Variable N  Mean Std Dev 
25th 
Pctl Median 
75th 
Pctl Min Max 
Age (years) 
Diabetes Duration (yrs) 
Average SBP (%) 
Average DBP (%) 
BMI (%) 
Waist/height ratio 
Growth velocity (cm/yr) 
Hemoglobin A1c (%) 
ACR (mg/g) 
α-klotho (pg/mL) 
eGFR (ml/kg/1.73m2) 
Serum Uric Acid (mg/dL) 
Creatinine (mg/dL) 
Triglycerides (mg/dL) 
Total cholesterol (mg/dL) 
LDL (mg/dL) 
HDL (mg/dL) 
97 
97 
90 
90 
90 
74 
96 
97 
88 
79 
86 
93 
93 
97 
97 
97 
97 
 15.82 
7.02 
54.43 
69.16 
66.01 
0.48 
2.77 
8.08 
16.48 
1301.88 
99.85 
3.79 
1.65 
103.12 
165.90 
90.15 
56.95 
2.89 
3.81 
23.88 
16.88 
29.37 
0.06 
2.68 
1.31 
18.83 
569.01 
20.79 
0.95 
9.40 
69.76 
27.40 
23.91 
11.67 
13.87 
4.18 
36.91 
59.91 
49.28 
0.44 
0.50 
7.30 
5.50 
871.44 
87.05 
3.10 
0.60 
62.00 
147.00 
76.00 
49.00 
15.44 
6.34 
53.81 
71.16 
75.88 
0.47 
1.60 
8.00 
8.95 
1204.71 
96.49 
3.70 
0.70 
90.00 
163.00 
89.00 
56.00 
17.73 
9.65 
74.03 
80.41 
88.97 
0.53 
4.90 
8.60 
19.30 
1555.23 
109.75 
4.40 
0.80 
120.00 
184.00 
102.00 
65.00 
10.04 
2.08 
1.25 
20.74 
0.06 
0.36 
0.00 
5.51 
0.00 
439.65 
61.35 
1.90 
0.40 
23.00 
72.00 
11.00 
34.00 
23.57 
17.63 
94.91 
92.64 
99.05 
0.66 
12.00 
11.94 
90.00 
3334.83 
179.25 
6.30 
91.30 
492.00 
245.00 
150.00 
86.00 
 
3.1.2 Categorical variables 
The descriptive analysis of categorical variables was based on 97 eligible subjects and 6 selected 
continuous variables (Table 2). For race, white and African American (AA) are the only two 
races that are being considered. Central Obesity was defined as waist/height ratio ≥ 0.5. Waist 
circumference was coded as 0, 1, 2, 3, 4, 5, 6, corresponding to standardized percentiles groups 
of 0%~10%, 10%~25%, 25%~50%, 50%~75%, 75%~85%, 85%~90% and 90%~100%. A 
dichotomous variable for Hemoglobin A1c was created and the cut point was 7.5 based on 
previous literature. Values higher than 7.5 indicated less glycemic control and values less than 
7.5 indicated more glycemic control. ACR was divided into two groups. Values less than or 
equal to 30 were classified into the normal group and values larger than 30 were classified into 
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the abnormal group. Most subjects were white and had no central obesity. Few children had a 
large waist circumference after adjusting for their age, sex, and race. Subjects whose HbA1c ≥ 
7.5 were nearly two times more than whose HbA1c < 7.5. 74 out of 88 subjects had normal 
ACR. 
 
Table 2. Descriptive statistics for categorical variables 
Variable Frequency Percent 
Sex 97  
Male 50 51.6 
Female 47 48.4 
Race 95  
White 86 90.6 
AA 9 9.4 
Central Obesity 75  
Yes 25 33.8 
No 49 66.2 
Waist Percentage 73  
0% 6 8.3 
10% 11 15.3 
25% 12 16.7 
50% 25 34.7 
75% 9 12.5 
85% 3 4.2 
90% 6 8.3 
Hemoglobin A1c (%) 97  
< 7.5 32 33.0 
≥ 7.5 65 67.0 
ACR (mg/g) 89  
Normal 74 84.1 
Abnormal 14 15.9 
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3.2 CORRELATIONS 
3.2.1 α-klotho and independent variables 
Correlations between soluble α-klotho (N=79) and other variables are shown in Table 4. 
Statistically significant negative correlations are noted between soluble α-klotho and age (r=-
0.32, p=0.004), diabetes durations (r=-0.45, p<0.0001), waist/height ratio (r=-0.38, p=0.004) and 
HbA1c (r=-0.30, p=0.007). A significant positive correlation is noted between soluble α-klotho 
and growth velocity (r=0.24, p=0.04). 
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Table 3. Correlations between α-klotho and other independent variables 
Variable R p-value N 
Age (years) -0.32 0.004 79 
Diabetes Duration(yrs) -0.45 <0.0001 79 
Average SBP (%) 0.008 0.95 72 
Average DBP (%) -0.08 0.49 72 
BMI % -0.06 0.59 72 
Waist/height ratio -0.38 0.004 57 
Growth velocity (cm/yrs) 0.24 0.04 78 
Hemoglobin A1c (%) -0.30 0.007 79 
ACR (mg/g) 0.02 0.89 75 
Creatinine (mg/dL) 0.06 0.61 78 
Triglycerides (mg/dL) -0.12 0.31 79 
Total cholesterol (mg/dL) -0.11 0.34 79 
LDL (mg/dL) -0.06 0.59 79 
HDL (mg/dL) -0.10 0.38 79 
 
 
3.2.2 Estimated GFR and independent variables 
Correlations were examined between eGFR (N=86) and other independent (Table 3). Significant 
positive correlations are found between eGFR and average DBP (r=0.30, p=0.007) and 
waist/height ratio (r=0.35, p=0.004). Significant negative correlations are found between eGFR 
and growth velocity (r=-0.29, p=0.007) and creatinine (r=-0.34, p=0.001). 
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Table 4. Correlations between eGFR and other independent variables 
Variable R p-value N 
Age (years) 0.10 0.37 86 
Diabetes Duration(yrs) -0.14 0.18 86 
Average SBP (%) 0.07 0.52 81 
Average DBP (%) 0.30 0.007 81 
BMI % 0.07 0.56 81 
waist/height ratio 0.35 0.004 66 
Growth velocity (cmy/yr) -0.29 0.007 85 
Hemoglobin A1c (%) 0.19 0.08 86 
ACR (mg/g) 0.19 0.10 78 
Creatinine (mg/dL) -0.34 0.001 86 
Triglycerides (mg/dL) 0.10 0.34 86 
Total cholesterol (mg/dL) 0.17 0.11 86 
LDL (mg/dL) 0.12 0.28 86 
HDL (mg/dL) 0.13 0.23 86 
 
3.2.3 Serum uric acid and independent variables 
Correlations between serum uric acid (N=93) and other variables are shown below (Table 5). A 
significant negative correlation between serum uric acid and HbA1c (r=-0.24, p=0.02) is noted. 
Significant positive correlations between serum uric acid and age (r=0.27, p=0.009) and 
creatinine (r=0.47, p<0.0001). 
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Table 5. Correlations between serum uric acid and other independent variables 
Variable R p-value N 
Age (years) 0.27 0.009 93 
Diabetes Duration(yrs) 0.01 0.90 93 
Average SBP (%) 0.05 0.63 86 
Average DBP (%) -0.14 0.20 86 
BMI % 0.13 0.22 86 
Waist/height ratio 0.02 0.85 70 
Growth velocity (cm/yrs) -0.07 0.50 92 
Hemoglobin A1c (%) -0.24 0.02 93 
ACR (mg/g) -0.06 0.58 85 
Creatinine (mg/dL) 0.47 <0.0001 93 
Triglycerides (mg/dL) 0.02 0.84 93 
Total cholesterol (mg/dL) -0.17 0.11 93 
LDL (mg/dL) -0.16 0.13 93 
HDL (mg/dL) -0.09 0.40 93 
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3.3 TRANSFORMATIONS OF DEPENDENT VARIABLES 
 
 
Figure 1. Distributions of dependent variables and transformations 
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Before performing univariable analysis, the normality of dependent variables eGFR, α-klotho, 
and serum uric acid were checked. Figure 1 displays histogram analysis of normality. The left 
three graphs are histograms of three dependent variables without transformation. All of them are 
positive-skewed showing some departures from normality may exist. The right three graphs are 
histograms of three dependent variables with log transformation. After log transformation, all 
three dependent variables seemed to be normally distributed. Hence, log transformation of these 
three dependent variables were used in the modelling. 
3.4 UNIVARIABLE REGRESSION 
Univariable regression models between three potential biomarkers and each independent variable 
were built to assess whether there was a statistically significant association between each 
biomarker and each independent variable. 
3.4.1 Log (α-klotho) 
Table 6 shows the univariable regression results between log (α-klotho) and each independent 
variable. Log (α-klotho) was significantly associated with age (p=0.004, R2= 0.104), diabetes 
duration (p<0.0001, R2= 0.208), waist/height ratio (p=0.007, R2=0.126), growth velocity (p=0.027, 
R2=0.063), HbA1c (p=0.009, R2=0.087), Creatinine (p=0.012, R2=0.080), central obesity (p=0.051, 
R2=0.069), and HbA1c group (p=0.037, R2=0.055).  
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Table 6. Univariable regression models for log α-klotho 
Variable DF Parameter Estimate 
Standard 
Error t Value P-value R-Square 
Age (years) 1 -0.046 0.015 -2.99 0.004 0.104 
Diabetes Duration(yrs) 1 -0.049 0.011 -4.49 <.0001 0.208 
Average SBP (%) 1 0.001 0.002 0.47 0.643 0.003 
Average DBP (%) 1 -0.003 0.003 -1.09 0.280 0.017 
BMI % 1 0.001 0.002 0.76 0.452 0.008 
Waist/height ratio 1 -2.374 0.851 -2.79 0.007 0.126 
Growth velocity (cm/yrs) 1 0.038 0.017 2.25 0.027 0.063 
Hemoglobin A1c (%) 1 -0.094 0.035 -2.70 0.009 0.087 
ACR (mg/g) 1 0.001 0.002 0.44 0.660 0.003 
Creatinine (mg/dL) 1 0.012 0.005 2.57 0.012 0.080 
Triglycerides (mg/dL) 1 -0.001 0.001 -1.15 0.254 0.017 
Total cholesterol (mg/dL) 1 -0.002 0.002 -1.29 0.199 0.021 
LDL (mg/dL) 1 -0.002 0.002 -1.09 0.278 0.015 
HDL (mg/dL) 1 0.002 0.002 1.00 0.320 0.012 
Sex 1 0.128 0.094 1.36 0.177 0.024 
Race 1 0.105 0.167 0.63 0.532 0.005 
Central Obesity 1 -0.228 0.115 -1.99 0.051 0.069 
Waist percentage 1 -0.034 0.035 -0.97 0.336 0.018 
HbA1c group 1 -0.207 0.097 -2.12 0.038 0.055 
ACR group 1 0.034 0.126 0.27 0.789 0.001 
 
3.4.2 Log (eGFR) 
Table 7 displays univariable regression results between log (eGFR) and each independent 
variable. Log (eGFR) was significantly associated with the average DBP (p=0.019, R2=0.068), 
waist/height ratio (p=0.027, R2=0.074), growth velocity (p=0.016, R2=0.068), HbA1c (p=0.006, 
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R2=0.087), sex (p=0.027, R2=0.057), race (p=0.041, R2=0.050), central obesity (p=0.044, R2=0.062), and 
HbA1c group (p=0.042, R2=0.048).   
 
Table 7. Univariable regression models for log eGFR 
Variable DF Parameter Estimate 
Standard 
Error t Value p-value R-Square 
Age (years) 1 0.005 0.008 0.71 0.483 0.006 
Diabetes Duration(yrs) 1 -0.006 0.006 -1.07 0.286 0.014 
Average SBP (%) 1 0.001 0.001 0.55 0.585 0.004 
Average DBP (%) 1 0.003 0.001 2.39 0.019 0.068 
BMI % 1 0.0003 0.001 0.45 0.655 0.003 
Waist/height ratio 1 1.013 0.449 2.26 0.027 0.074 
Growth velocity (cm/yrs) 1 -0.019 0.008 -2.45 0.016 0.068 
Hemoglobin A1c (%) 1 0.044 0.016 2.82 0.006 0.087 
ACR (mg/g) 1 0.001 0.001 0.90 0.372 0.011 
Creatinine (mg/dL) 1 -0.002 0.002 -1.05 0.298 0.013 
Triglycerides (mg/dL) 1 0.0003 0.0002 0.92 0.361 0.010 
Total cholesterol (mg/dL) 1 0.001 0.001 1.48 0.142 0.026 
LDL (mg/dL) 1 0.001 0.001 1.48 0.143 0.025 
HDL (mg/dL) 1 0.002 0.002 1.00 0.320 0.012 
Sex 1 0.093 0.041 2.25 0.027 0.057 
Race 1 -0.168 0.081 -2.08 0.041 0.050 
Central Obesity 1 0.112 0.054 2.06 0.044 0.062 
Waist percentage 1 0.017 0.018 0.97 0.334 0.015 
HbA1c group 1 0.090 0.044 2.06 0.042 0.048 
ACR group 1 0.079 0.057 1.40 0.167 0.0250 
 
 
 32 
3.4.3 Log (serum uric acid) 
Table 8 shows univariable regression results between log (serum uric acid) and each independent 
variable. Log (serum uric acid) was significantly associated with age (p=0.010, R2= 0.071), 
HbA1c (p=0.023, R2=0.056), sex (p=0.019, R2=0.059) and HbA1c group (p=0.001, R2=0.123).   
 
Table 8. Univariable regression models for log serum uric acid 
Variable DF Parameter Estimate 
Standard 
Error t Value p-value| R-Square 
Age (years) 1 0.023 0.009 2.63 0.010 0.071 
Diabetes Duration(yrs) 1 0.002 0.007 0.24 0.811 0.001 
Average SBP (%) 1 0.0001 0.001 0.07 0.943 0.0001 
Average DBP (%) 1 -0.002 0.002 -1.34 0.184 0.021 
BMI % 1 0.001 0.001 1.08 0.284 0.014 
Waist/height ratio 1 -0.086 0.566 -0.15 0.880 0.0003 
Growth velocity (cm/yrs) 1 -0.006 0.010 -0.62 0.538 0.004 
Hemoglobin A1c (%) 1 -0.045 0.019 -2.32 0.023 0.056 
ACR (mg/g) 1 -0.001 0.002 -0.68 0.499 0.006 
Creatinine (mg/dL) 1 0.001 0.003 0.50 0.620 0.003 
Triglycerides (mg/dL) 1 -0.00002 0.0004 -0.05 0.957 0.0001 
Total cholesterol (mg/dL) 1 -0.001 0.001 -1.36 0.176 0.020 
LDL (mg/dL) 1 -0.002 0.001 -1.57 0.120 0.026 
HDL (mg/dL) 1 -0.002 0.002 -0.73 0.464 0.006 
Sex 1 -0.122 0.051 -2.39 0.019 0.059 
Race 1 0.023 0.092 0.25 0.801 0.001 
Central Obesity 1 0.020 0.070 0.29 0.774 0.001 
Waist percentile 1 0.011 0.021 0.55 0.587 0.005 
HbA1c group 1 -0.188 0.052 -3.58 0.001 0.123 
ACR group 1 -0.071 0.076 -0.93 0.353 0.010 
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3.5 MULTIPLE REGRESSION  
3.5.1 Variable selection criteria 
Before fitting multiple regression models, correlations between each independent variable were 
checked to avoid any highly-correlated variables, which may cause multicollinearity issues. LDL 
and total cholesterol were highly-correlated (r=0.83). As a result, LDL and total cholesterol were 
not considered in the same multiple regression model. In our study, total cholesterol was 
included in the variable list. In addition, central obesity was created based on waist/height ratio 
and it is commonly used in diabetic-related research as a measure of risk. Because we were 
interested in determining the relationship between novel biomarkers and (1) ACR, the current 
gold standard to detect early DN and (2) HbA1c, which measured diabetes control, ACR and 
HbA1c included as continuous variables were candidate predictors. Hence, the maximum model 
contained age, diabetic duration, average SBP percentile, average DBP percentile, BMI 
percentile, growth velocity, HbA1c, ACR, Creatinine, Triglycerides, total cholesterol, HDL, sex, 
race, central obesity and waist percentile. 
3.5.2 Cross Validation 
Cross-validation was used to select variables and assess the accuracy of predictive models and 
include 2-fold, 5-fold, 10-fold and n-fold. Different model selection criteria such as adjusted R-
square, AIC, BIC, Mallow’s Cp and CV PRESS were estimated in order to choose the best 
model. Here, backward elimination was used as the model selection method and CV was used as 
the selection and stopping criterion. CV here stands for predicted residual sum of square with k-
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fold cross-validation. It was used as the model selection criterion instead of significance levels 
because CV can provide the fit of candidate models and their model structures by using cross-
validation. Predicted residual sum of square can measure the how predictive the model is when 
new observations are added. Moreover, the p-value was not a good selection rule when the 
sample size was small. 
In SAS, the maximum models were constructed based on the backwards elimination. At 
each step, the variable with the lowest CV PRESS value when removed from the model was 
dropped from the model that was constructed at the last step. The selection steps ends when the 
CV PRESS does not decrease any further when any other variables are removed from the model. 
Thus, the final model was the model with the lowest CV PRESS.  
3.5.2.1 Log (α-klotho) model 
Table 9 displays selected variables based on selection criteria and cross-validation methods for 
log (α-klotho) model. Different k-fold cross-validation methods selected different numbers of 
variables. For each cross-validation method, the adjusted R-square selection criterion tended to 
include more variables than any other selection criteria. The consistent selection results could be 
reached when BIC, Mallow’s Cp and CV PRESS were used as selection criteria for each cross-
validation method.  
Adjusted R-square would not be used as the model selection criteria here because 
maximizing adjusted R-square could not minimize the predicted residual sum of square and the 
adjusted R-square tended to reach the maximum at the early selection step. The same variables 
were selected based on BIC, Mallow’s Cp and CV PRESS. As a result, any one of those three 
model selection criteria could be chosen as the selection criterion for the log (α-klotho) model. 
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Table 9. Selected variables for different model selection criteria and k-fold cross-validation for log(α-klotho) model 
 No CV 2-fold CV 5-fold CV 10-fold CV n-fold CV 
Adjusted R-
square 
HbA1c, SBP%, 
growth velocity, 
ACR, TG, 
Cholesterol, 
HDL, central 
obesity, waist% 
Diabetic duration, 
age, SBP%, 
DBP%, growth 
velocity, ACR, 
Creatinine, TG, 
Cholesterol, HDL 
Diabetic duration, 
age, SBP%, 
DBP%, BMI%, 
growth velocity, 
Creatinine, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
HbA1c, age, 
DBP%, growth 
velocity, ACR, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
HbA1c, SBP%, 
growth velocity, 
ACR, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
AIC HbA1c, SBP%, 
growth velocity, 
ACR, TG, 
Cholesterol, 
HDL, central 
obesity, waist% 
Diabetic duration, 
age, SBP%, 
DBP%, growth 
velocity, ACR, 
Creatinine, TG, 
Cholesterol, HDL 
Growth velocity, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
HbA1c, growth 
velocity, TG, 
Cholesterol, HDL, 
central obesity 
HbA1c, SBP%, 
growth velocity, 
ACR, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
BIC HbA1c, growth 
velocity, ACR, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
Diabetic duration, 
age, SBP%, 
DBP%, growth 
velocity, ACR, 
Creatinine, TG, 
Cholesterol, HDL 
Growth velocity, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
HbA1c, growth 
velocity, TG, 
Cholesterol, HDL, 
central obesity 
HbA1c, growth 
velocity, ACR, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
Mallow’s 
Cp 
HbA1c, growth 
velocity, ACR, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
Diabetic duration, 
age, SBP%, 
DBP%, growth 
velocity, ACR, 
Creatinine, TG, 
Cholesterol, HDL 
Growth velocity, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
HbA1c, growth 
velocity, TG, 
Cholesterol, HDL, 
central obesity 
HbA1c, growth 
velocity, ACR, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
CV PRESS 
or PRESS 
HbA1c, growth 
velocity, ACR, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
Diabetic duration, 
age, SBP%, 
DBP%, growth 
velocity, ACR, 
Creatinine, TG, 
Cholesterol, HDL 
Growth velocity, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
HbA1c, growth 
velocity, TG, 
Cholesterol, HDL, 
central obesity 
HbA1c, growth 
velocity, ACR, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
 
Table 10. Comparisons of model selection criteria for log (α-klotho) model 
 R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
10-fold CV 0.3710 0.2717 -51.10 -91.87 3.18 5.01 
n-fold CV 0.4236 0.2955 -51.03 -88.55 4.33 5.11 
 
Because 2-fold cross-validation and 5-fold cross-validation methods introduced more 
bias for true errors and predicted errors than 10-fold and n-fold cross-validation methods, only 
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10 and n-fold cross validation methods were considered when selecting models. Table 10 shows 
values of different model selection criteria for 10-fold and n-fold cross-validation methods. Since 
R-square of n-fold cross-validation was larger than the 10-fold one, and there were no significant 
differences when comparing other model selection criteria. Thus, the n-fold cross-validation 
method appears to be the most appropriate method for the α-klotho model. 
However, because there were missing data, especially for central obesity and waist 
percentile, the sample size of the selected model is small. Seventy-nine subjects had data for α-
klotho, but only 45 subjects did not have missing values for variables in the maximum models 
and thus only 45 subjects were included in the regression analysis. Hence, models excluding 
variables with many missing values should be constructed and compared to the n-fold cross-
validation model. 
When central obesity and waist percentile were excluded from the model, the sample size 
increased from 45 to 66. Table 11 displays values of different model selection criteria for n-fold 
cross-validation model with and without central obesity and waist percentile. For the model 
without central obesity and waist percentile, the selected model included HbA1c, age, ACR, 
Triglycerides and HDL. The R-square was greatly reduced, which indicated that less variability 
of the dependent variable could be explained by the model. Mallow’s Cp and CV PRESS for the 
model without central obesity and waist percentile were appreciably greater than the one with 
central obesity and waist percentile, which suggested that the model without central obesity and 
waist percentile had a poor fit and did not predict new observations well. Although the model 
with central obesity and waist percentile had small sample size, the model was more reasonable 
and predictive. 
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Table 11. Model selection criteria with or without central obesity and waist% for α-klotho model 
N-fold CV N R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
With central 
obesity and 
waist% 
45 0.4236 0.2955 -51.03 -88.55 4.33 5.11 
Without central 
obesity and 
waist% 
66 0.2388 0.1889 -64.21 -129.85 7.68 8.81 
 
Table 12. Model selection criteria without central obesity and waist% for non-missing dataset for α-klotho 
model 
N-fold CV  R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
Without central 
obesity and 
waist% for non-
missing dataset 
45 0.3010 0.2311 -50.35 -93.63 3.21 4.67 
 
A subset analysis was performed on the dataset excluding missing values for central 
obesity and waist percentile. The sample size was 45, which was the same as the first selected 
model. But this time central obesity and waist percentile were not considered as candidate 
variables in the maximum model. This model contained diabetic duration, growth velocity, 
Creatinine and Triglycerides. Table 12 displays model selection criteria of this model. 
Comparing this model with the model without central obesity and waist percentile on the full 
dataset, R-square was largely improved. The Mallow’s Cp and CV PRESS decreased from 9 to 
less than 5, which indicated this model had a better fit and it was a more predictive model after 
removing 21 subjects with missing values of central obesity and waist percentile. Comparing this 
model with the model with central obesity and waist percentile, the model with central obesity 
and waist percentile had a higher R-square. In addition, central obesity was selected in that 
model, which indicated it was an important predictor. Therefore, central obesity and waist 
percentile should be retained in the maximum model.  
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Thus, the best log (α-klotho) model was the one using n-fold cross-validation method, 
BIC or Mallow’s Cp or CV PRESS as model selection criterion, and includes central obesity and 
waist percentile. This method contained HbA1c, growth velocity, Triglycerides, total 
Cholesterol, HDL and central obesity. The parameter estimates and p-values are shown in the 
Table 13. 
 
Table 13. Parameter estimates and p-values for the best selected log(α-klotho) model 
Parameter Estimate Standard Error p-value 
Intercept 9.053 0.821 <.0001 
HbA1c -0.049 0.034 0.158 
Growth velocity 0.039 0.020 0.061 
ACR 0.003 0.002 0.179 
Triglycerides -0.002 0.001 0.030 
Total Cholesterol 0.003 0.002 0.133 
HDL -0.015 0.006 0.010 
Central obesity -3.037 1.781 0.097 
Waist% 0.084 0.066 0.210 
 
For the best selected log (α-klotho) model, R-square = 0.424, AIC = -51.03, BIC =                  
-88.55, Mallow’s Cp = 4.33, CV PRESS = 5.11. 
3.5.2.2 Log (eGFR) model 
Table 14 displays selected variables based on selection criteria and cross-validation methods for 
the log (eGFR) model. Except for no cross-validation, other model selections based on the cross-
validation method selected the same variables no matter what selection criterion was used. This 
also suggested the model fitted well and all model selection criteria reached the same results.  
 
 
 39 
 
Table 14. Selected variables for different model selection criteria and k-fold cross-validation for log(eGFR) model 
 
 No CV 2-fold CV 5-fold CV 10-fold CV n-fold CV 
Adjusted 
R-square 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, 
central obesity 
HbA1c, diabetic 
duration, DBP%, 
SBP%, ACR, 
Creatinine, TG, 
Cholesterol, sex, 
race, central obesity, 
waist% 
HbA1c, age, 
growth velocity, 
ACR, Creatinine, 
sex, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, 
central obesity 
AIC HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, 
central obesity 
HbA1c, diabetic 
duration, DBP%, 
SBP%, ACR, 
Creatinine, TG, 
Cholesterol, sex, 
race, central obesity, 
waist% 
HbA1c, age, 
growth velocity, 
ACR, Creatinine, 
sex, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
Creatinine, 
Cholesterol, 
central obesity 
BIC HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, 
central obesity 
Diabetic duration, 
ACR, Creatinine, TG, 
Cholesterol, sex, 
race, central obesity, 
waist% 
HbA1c, age, 
growth velocity, 
ACR, Creatinine, 
sex, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
Creatinine, 
Cholesterol, 
central obesity 
Mallow’s 
Cp 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, 
central obesity 
HbA1c, diabetic 
duration, DBP%, 
SBP%, ACR, 
Creatinine, TG, 
Cholesterol, sex, 
race, central obesity, 
waist% 
HbA1c, age, 
growth velocity, 
ACR, Creatinine, 
sex, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
Creatinine, 
Cholesterol, 
central obesity 
CV 
PRESS or 
PRESS 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, 
central obesity 
Diabetic duration, 
ACR, Creatinine, TG, 
Cholesterol, sex, 
race, central obesity, 
waist% 
HbA1c, age, 
growth velocity, 
ACR, Creatinine, 
sex, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
ACR, Creatinine, 
Cholesterol, central 
obesity, waist% 
HbA1c, DBP%, 
growth velocity, 
Creatinine, 
Cholesterol, 
central obesity  
 
Because 10-fold cross-validation and n-fold cross-validation were less biased than the 
others, the selected model was chosen based on the comparisons of different model selection 
criteria (Table 15). Here, n-fold cross-validation would be used to select the best eGFR model. 
Compared to the two cross-validation methods, there were no appreciable difference in R-square, 
AIC, BIC, and CV PRESS. Looking at the p-values of selected variables, the p-values of n-fold 
cross-validation were all significant or close to the significance level. Moreover, the n-fold cross-
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validation method is more precise than the 10-fold cross-validation method. As a result, the n-
fold cross-validation method was used in the eGFR model. 
 
Table 15. Comparisons of model selection criteria for log (eGFR) model 
 R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
10-fold CV 0.6242 0.5543 -139.14 -183.24 1.56 1.26 
n-fold CV 0.6176 0.5568 -140.23 -185.62 0.18 1.24 
 
There were many missing values for central obesity and waist percentile. The sample size 
of the model with central obesity and waist percentile was 52. The sample size of the model 
without central obesity and waist percentile was 70. Therefore, the model for 70 subjects without 
central obesity and waist percentile and the subset analysis for 52 without central obesity and 
waist percentile were constructed following the previous procedures and logic of the α-klotho 
model. The tables of comparisons of model selection criteria for the three models were presented 
in the Appendix A.  
After comparisons of three eGFR models with and without central obesity and waist 
percentile, using similar logic and analysis as α-klotho model, the best selected model for log 
(eGFR) used 10-fold cross-validation method and included central obesity and waist percentile. 
This model contained HbA1c, DBP percentile, growth velocity, ACR, Creatinine, Cholesterol 
and central obesity. The parameter estimates and p-values are shown in the Table 16. 
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Table 16. Parameter estimates and p-values for the best selected log (eGFR) model 
Parameter Estimate Standard Error p-value 
Intercept 4.108 0.316 <.0001 
HbA1c 0.028 0.015 0.069 
DBP% 0.003 0.001 0.024 
Growth velocity -0.028 0.010 0.006 
ACR 0.003 0.001 0.006 
Creatinine -0.826 0.146 <.0001 
Cholesterol 0.001 0.001 0.138 
Central obesity 0.967 0.433 0.031 
 
For the best selected log (eGFR) model, R-square = 0.618, AIC = -140.23, BIC =              
-185.62, Mallow’s Cp = 0.18, CV PRESS = 1.24. 
3.5.2.3 Log (serum uric acid) model 
Table 17 displays selected variables based on selection criteria and cross-validation methods for 
the log (serum uric acid) model. For each cross-validation method, selected variables were the 
same for BIC and CV PRESS. Thus, BIC or CV PRESS could be used as the selection criterion.  
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Table 17. Selected variables for different model selection criteria and k-fold cross-validation for log(serum uric acid) 
model 
 No CV 2-fold CV 5-fold CV 10-fold CV n-fold CV 
Adjusted 
R-square 
HbA1c, diabetic 
duration, age, ACR, 
Creatinine, TG, 
Cholesterol, HDL, 
gender, race, central 
obesity, waist% 
HbA1c, ACR, 
Creatinine, TG, 
Cholesterol, HDL, 
gender, race, central 
obesity, waist% 
All variables HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, race, central 
obesity, waist% 
HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, gender, race, 
central obesity, 
waist% 
AIC HbA1c, diabetic 
duration, age, ACR, 
Creatinine, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
HbA1c, ACR, 
Creatinine, TG, 
Cholesterol, HDL, 
gender, race, central 
obesity, waist% 
HbA1c, Diabetic 
duration, age, 
Creatinine, TG, 
Cholesterol 
HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
BIC HbA1c, diabetic 
duration, age, ACR, 
Creatinine, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
HbA1c, ACR, 
Creatinine, HDL, 
gender, central 
obesity, waist% 
HbA1c, Diabetic 
duration, age, 
Creatinine, TG, 
Cholesterol 
HbA1c, diabetic 
duration, ACR, 
Creatinine, TG, 
Cholesterol, HDL 
HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
Mallow’s 
Cp 
HbA1c, diabetic 
duration, age, ACR, 
Creatinine, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
HbA1c, ACR, 
Creatinine, HDL, 
gender, central 
obesity, waist% 
HbA1c, Diabetic 
duration, age, 
Creatinine, TG, 
Cholesterol 
HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
CV 
PRESS or 
PRESS 
HbA1c, diabetic 
duration, age, ACR, 
Creatinine, TG, 
Cholesterol, HDL, 
central obesity, 
waist% 
HbA1c, ACR, 
Creatinine, HDL, 
gender, central 
obesity, waist% 
HbA1c, Diabetic 
duration, age, 
Creatinine, TG, 
Cholesterol 
HbA1c, diabetic 
duration, ACR, 
Creatinine, TG, 
Cholesterol, HDL 
HbA1c, diabetic 
duration, age, 
ACR, Creatinine, 
TG, Cholesterol, 
HDL, central 
obesity, waist% 
 
Table 18. Comparisons of model selection criteria for log (serum uric acid) model 
 R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
10-fold CV 0.3570 0.2591 -89.63 -141.17 8.66 3.61 
n-fold CV 0.4467 0.3181 -91.75 -138.40 8.15 3.48 
 
Table 18 shows the comparisons of model selection criteria for the serum uric acid 
model. The comparisons were conducted only between 10-fold and n-fold cross-validation. The 
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model selection criteria for two cross-validation methods looked similar to each other. However,  
n-fold cross-validation had higher R-square and all p-values of selected predictors were less than 
0.2. Hence, the n-fold cross-validation method was used to construct the serum uric acid model. 
There were many missing data for central obesity and waist percentile. The sample size 
of the model with central obesity and waist percentile was 54. The sample size of the model 
without central obesity and waist percentile was 75. Therefore, the model for 75 subjects without 
central obesity and waist percentile, and the subset analysis for 54 without central obesity and 
waist percentile, were constructed following on the previous procedures and logic of the α-klotho 
model. The tables of comparisons of model selection criteria for the three models were presented 
in Appendix A.  
After comparisons of three serum uric acid models concerning about central obesity and 
waist percentile, based on a similar logic and analysis as α-klotho model, the best selected model 
for log (serum uric acid) used the n-fold cross-validation method and included central obesity 
and waist percentile. This model contained HbA1c, diabetic duration, age, ACR, Creatinine, 
Triglycerides, Cholesterol, HDL, central obesity, and waist percentile. The parameter estimates 
and p-values are shown in Table 19. 
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Table 19. Parameter estimates and p-values for the best selected log (serum uric acid) model 
Parameter Estimate Standard Error p-value 
Intercept 1.902 0.608 0.003 
HbA1c -0.050 0.028 0.082 
Diabetic duration -0.015 0.012 0.198 
Age 0.036 0.018 0.048 
ACR -0.002 0.002 0.200 
Creatinine 0.652 0.268 0.020 
TG 0.001 0.001 0.081 
Cholesterol -0.003 0.001 0.048 
HDL 0.007 0.004 0.062 
Central obesity -2.915 1.324 0.033 
Waist% 0.099 0.048 0.047 
 
For the best selected log (serum uric acid) model, R-square = 0.447, AIC = -91.75, BIC = 
-138.40, Mallow’s Cp = 8.15, CV PRESS = 3.48. 
3.6 REGRESSION DIAGNOSTICS 
3.6.1 Collinearity  
Collinearity was measured by Variance Inflation Factor (VIF). VIF=1 indicates perfect 
prediction and no effects of collinearity. Large deviations of VIF from 1 indicates collinearity. 
Generally, VIF ≥ 10 indicates the existence of collinearity issues. 
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3.6.1.1  Log (α-klotho) model 
From Table 20, since all the VIF values were less than 10, no collinearity issue was presented for 
the log (α-klotho) model. 
 
Table 20. VIF of log (α-klotho) model 
 HbA1c Growth velocity TG ACR Cholesterol HDL 
Central 
obesity Waist% 
VIF 1.22 1.32 1.77 1.39 1.61 1.53 4.09 3.67 
 
3.6.1.2 Log (eGFR) model 
From Table 21, since all the VIF values were less than 10, no collinearity issue was presented for 
the log (α-klotho) model. 
 
Table 21. VIF of log (eGFR) model 
 HbA1c Growth velocity ACR Cholesterol DBP% Creatinine 
Central 
obesity 
VIF 1.10 1.61 1.30 1.04 1.04 1.31 1.52 
 
3.6.1.3 Log (serum uric acid) model 
From Table 22, since all the VIF values were less than 10, no collinearity issue was presented for 
the log (serum uric acid) model. 
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Table 22. VIF of log (serum uric acid) model 
 HbA1c Age Cholesterol TG Creatinine 
VIF 1.39 1.95 1.56 1.75 1.60 
 Central obesity HDL Waist% 
Diabetic 
Duration ACR 
VIF 5.74 1.48 5.25 1.72 1.26 
 
3.6.2 Linear regression assumptions checking 
3.6.2.1 Linear regression assumptions 
There are five assumptions for linear regression. They are: 
1) Existence: For each specific combination of the fixed x’s, y is a random variable 
with a certain probability distribution. 
2) Independence: The y values are statistically independent of each other. 
3) Linearity: The mean of y for each specific combination of x1, x2, x3, x4, … , xk is a 
linear function of x1, x2, x3, x4, … , xk. 
4) Homoscedasticity: The variance of y is the same for any fixed combination of x1, 
x2, x3, x4, … , xk. 
5) Normality: For any fixed combination of x1, x2, x3, x4, … , xk, the random 
variable y has a normal distribution. 
The three models should be checked whether they met all linear regression assumptions. 
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3.6.2.2 Existence and Independence 
From the study design, children were recruited separately and no children had blood 
relationships. We assumed each of three dependent variables had a certain probablity 
distribution. Therefore, existence and independence assumptions were met for all three models. 
3.6.2.3 Linearity and Homoscedasticity 
Linearity and homoscedasticity could be assessed by using a plot of residuals versus predicted 
values. The residuals should be small and symmetric around 0. In addition, no obvious patterns 
of residuals suggested the linearity.  
Figure 2 displays the scatter plot of residuals by predicted values for the log (α-klotho) 
model. Almost all residuals were between -0.5 and 0.5. They were randomly distributed around 0 
and no other pattern was obviously presented. Hence, linearity and homoscedasticity 
assumptions were met for the log (α-klotho) model. 
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Figure 2. Scatter plot of residuals by predicted values for log (α-klotho) model 
 
 
Figure 3. Scatter plot of residuals by predicted values for log (eGFR) model 
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Figure 3 shows the scatter plot of residuals by predicted values for the log (eGFR) model. 
Most residuals fell between -0.2 to 0.2 and there was no obvious pattern for the residuals. Thus, 
the linearity assumption was met for the log (eGFR) model. 
Figure 4 is the scatter plot of residuals by predicted values for the log (serum uric acid) 
model. Most residuals were between -0.4 to 0.4 and they were symmetric and randomly 
distributed around 0. Also, there was no obvious pattern for the residuals. Hence, linearity and 
homoscedasticity assumptions were met for the log (serum uric acid) model. 
 
 
Figure 4. Scatter plot of residuals by predicted values for log (serum uric acid) model 
3.6.2.4 Normality 
The quantile-quantile plot (QQ plot) was used to access the normality assumptions for the three 
models. 
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Figure 5. QQ plot of residuals for log (α-klotho) model 
 
 
Figure 6. QQ plot of residuals for log (eGFR) model 
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Figure 7. QQ plot of residuals for log (serum uric acid) model 
 
From Figure 5-7, normality assumptions were met for all three models. 
In all, the log (α-klotho) model, log (eGFR) model and log (serum uric acid) model all 
met the five assumptions of linear regression. 
3.6.3 Problematic points 
Different types of plots and methods could be used to detect problematic points. Problematic 
points included high leverage points, outliers, and influential points. High leverage points could 
be examined by a plot of leverage analysis. Outliers could be examined by a plot of Studentized 
Residuals. Influential points could be examined by a plot of Cook’s Distance versus observation 
or DFFITS versus observation. The cut point formulas and values of three methods for the three 
models are shown in Table 23. 
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Table 23. Cut point formulas and values for the three models 
Leverage  Leverage Outlier Cook’s D |DFFITS| 
Cut point formula 2(k+1)/n ±2 of Studentized Residual 4/n 2√[(k+1)/n] 
Values for α-
klotho model 0.353 ±2 0.078 0.840 
Values for eGFR 
model 0.296 ±2 0.074 0.770 
Values for serum 
uric acid model 0.361 ±2 0.066 0.849 
k is number of predictors, n is number of observations in the model. 
3.6.3.1 Log (α-klotho) model 
Figure 8 displays plots of problematic points for the log (α-klotho) model. There were two 
outliers, subject 16 and subject 69, whose studentized residuals were larger than the cut point ±2. 
There was one high leverage point, subject 97, whose leverage was larger than cut point 0.353. 
There were three subjects (subject 16,69 and 91), who had high Cook’s D values above the cut 
point 0.078. In addition, subject 16, 69, 79 and 91 had the DEFFITS values below the cut point -
0.840. Generally, there were few problematic points. Thus, the log (α-klotho) model was 
considered as a good predictive model. Fit diagnostics for other methods and residuals by each 
predictor plots are shown in Appendix A. 
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Figure 8. Plots of problematic points for log (α-klotho) model 
 
3.6.3.2 Log (eGFR) model 
Figure 9 displays plots of problematic points for the log (eGFR) model. There was one outlier, 
subject 35, whose studentized residual was larger than the cut point ±2. There were two high 
leverage points, subject 47 and 75, whose leverages were larger than cut point 0.296. There were 
two subjects (subject 35 and 92), who had high Cook’s D values above the cut point 0.074. In 
addition, subject 35 and subject 92 had the DEFFITS values below or above the cut point 
±0.770. Generally, there were few problematic points. Hence, the log (eGFR) model was 
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considered as a good predictive model. Fit diagnostics for other methods and residuals by each 
predictor plots are shown in Appendix A. 
 
 
 
Figure 9. Plots of problematic points for log (eGFR) model 
3.6.3.3 Log (serum uric acid) model 
Figure 10 displays plots of problematic points for the log (serum uric acid) model. There were 
three outliers, subject 11, 41, and 93, whose studentized residuals were larger than the cut point 
±2. There were two high leverage points, subject 47 and 97, whose leverages were larger than 
cut point 0.361. There were three subjects (subject 52, 75, and 93) who had high Cook’s D 
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values above the cut point 0.066. In addition, subject 52, 75, and 93 had DEFFITS values below 
or above the cut point ±0.849. Generally, there were few problematic points, so the log (serum 
uric acid) model was considered as a good predictive model. Fit diagnostics for other methods 
and residuals by each predictor plots are shown in Appendix A. 
 
 
 
Figure 10. Plots of problematic points for log (serum uric acid) model 
 
Table 24. Comparisons of model selection criteria for three models 
 R-square AIC BIC Mallow’s Cp CV PRESS 
Log (α-klotho) model 0.4236 -51.03 -88.55 4.33 5.11 
Log (eGFR) model 0.6176 -140.23 -185.62 0.18 1.24 
Log (serum uric acid) model 0.4467 -91.75 -138.40 8.15 3.48 
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3.7 ACR MODELS 
ACR reflects the albuminuria level, which is the gold standard for predicting and screening the 
progression of DN. Hence, it is important to predict the ACR level using other variables and 
potential risk biomarkers.  
3.7.1 Transformation of ACR 
Because ACR was treated as the dependent variable in the ACR model, distribution needed to be 
checked to assess whether a log transformation was necessary. 
 
 
Figure 11. Distribution of ACR and the log transformation 
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Figure 11 shows histograms of the distribution of ACR and the log transformation. The 
left picture is the original ACR distribution and the right picture is the ACR distribution with log 
transformation. Since the original ACR distribution was extremely positive-skewed and log 
(ACR) distribution seemed normally-distributed, the log transformation of ACR was used as the 
dependent variable in the following modelling steps. 
3.7.2 ACR model with potential biomarkers 
After determining the appropriate transformation of the dependent variable, multiple linear 
regression models were constructed to see which variables were considered important predictors 
for ACR. 
Recent studies showed that ACR was related to age, diabetic duration years, and HbA1c. 
As a result, those three variables were forced into the ACR model. Since we wanted to see 
whether the three potential risk biomarkers were important predictors for the ACR level, those 
three biomarkers along with three forced variables were treated as the independent variables in 
the first ACR model. BMI percentile, waist circumference percentile and central obesity were 
excluded from the model because they had a substantial number of missing data and the sample 
size would increase by excluding them. 
Based on the previous results and discussions, the n-fold cross-validation method and 
backwards elimination were used to construct and select the ACR model. 
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Table 25. Parameter estimates and p-values for the log(ACR) model with three biomarkers 
Parameter Estimate Standard Error p-value 
Intercept 1.384 1.005 0.173 
HbA1c 0.191 0.091 0.040 
Diabetic Duration -0.009 0.032 0.788 
Age -0.026 0.046 0.578 
 
Table 25 shows parameter estimates and p-values for this ACR model. For this model, R-
square = 0.0751, AIC = 62.56, BIC = -2.77, Mallow’s Cp = 2.83, CV PRESS = 60.68.  
The results showed that none of the three risk biomarkers (α-klotho, eGFR, serum uric 
acid) were related to ACR and they were not important predictors for ACR.  
From parameter estimates and model selection criteria, this model could not be 
considered a good predictive model. The R-square was at an extremely low level, which 
indicated that only 7.5% variability of log (ACR) could be explained by selected variables. CV 
PRESS was extremely high, which indicated that this model had high residuals and was not 
predictive for new observations. Thus, we may seek other ACR models which can predict ACR 
better and involve other relevant predictors. 
3.7.3 ACR model with biomarkers and other variables 
Some other variables, such as SBP percentile, DBP percentile, LDL, HDL and Triglycerides, 
were considered candidate variables for predicting ACR. Hence, these variables, along with three 
forced variables and three potential risk biomarkers, were included as candidate variables in the 
ACR model to see whether those variables and biomarkers were important predictors for ACR. 
Based on the previous results and discussions, the n-fold cross-validation method and 
backwards elimination were used to construct and select the ACR model. 
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Table 26. Parameter estimates and p-values for the log(ACR) model with biomarkers and other 
variables 
Parameter Estimate Standard Error p-value 
Intercept -0.856 1.337 0.525 
HbA1c 0.227 0.094 0.019 
Diabetic Duration -0.021 0.033 0.524 
Age -0.0002 0.050 0.996 
SBP% 0.016 0.007 0.021 
DBP% -0.021 0.010 0.035 
TG 0.004 0.002 0.029 
HDL 0.032 0.011 0.008 
 
Table 26 shows parameter estimates and p-values for the ACR model with three 
biomarkers and other variables. For this model, R-square = 0.2751, AIC = 55.35, BIC = -2.20, 
Mallow’s Cp = 4.93, CV PRESS = 55.23.  
The results showed that none of the three risk biomarkers (α-klotho, eGFR, serum uric 
acid) were related to ACR. However, SBP percentile, DBP percentile, Triglycerides, and HDL 
were considered important predictors for ACR.  
For the ACR model with biomarkers and other variables, there was no collinearity issue. 
All linear regression assumptions were met. However, there were several problematic points for 
this model, which indicated this model was not as predictive as three biomarkers’ models. 
Relevant graphs are displayed in the Appendix A. 
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4.0  DISCUSSION AND CONCLUSION 
For three potential biomarkers, separate models were constructed using demographic and clinical 
data. Log transformation of the biomarkers were made and normality was achieved. 
α-klotho was negatively correlated with diabetic duration years and HbA1c, which 
indicated that α-klotho was associated with glycemic control and it could be a potential early risk 
biomarker for diabetic complications in children with T1D. However, α-klotho was not 
significantly correlated with ACR in this study. Future studies including longitudinal follow-up 
of subjects need to be done to assess the relationship between ACR and α-klotho. For the 
multiple regressions of log (α-klotho) model, after model selection and cross-validation, the final 
model included HbA1c, growth velocity, Triglycerides, total Cholesterol, HDL and central 
obesity. HbA1c was still an important predictor in the multiple regression model and it reflected 
that glycemic control plays a vital role in predicting α-klotho. Some clinical predictors 
(Triglycerides, total Cholesterol, HDL) that were not significant predictors in univariable 
regression analysis did become significant predictors in the final multiple regression models. It 
indicated that univariable regression analysis alone was not sufficient and predictive. Multiple 
regression analysis was necessary and may predict the model better than univariate. From the 
selected log (α-klotho) model, R-square was largely improved (R2=0.37), which meant this 
model had a relative better fit compared to individual univariable regression models.  
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eGFR was not correlated with HbA1c and ACR, which indicated that eGFR was not 
strongly associated with glycemic control and it may not be a potential early risk biomarker for 
diabetic complications in youth with T1D. However, the p-value between eGFR and HbA1c was 
close to 0.05, which indicated the weak association. Future studies about longitudinal follow-ups 
of subjects needed to be done to assess the relationship between eGFR and HbA1c. After fitting 
the multiple regression model for log (eGFR) and conducting model selections, HbA1c and ACR 
were both included in the selected model. Hence, glycemic control and albuminuria were 
important factors in predicting eGFR. Also, eGFR may be a potential early risk biomarker for 
DN and diabetic complications in children with T1D.   
Serum uric acid was negatively correlated with HbA1c. But the p-values were both 
between 0.05 and 0.1 and they were not high p-values. Significant correlations between eGFR 
and HbA1c or, ACR could be possibly derived if more subjects were enrolled in the study. After 
fitting the multiple regression model for log (serum uric acid) and conducting model selections, 
HbA1c and ACR were both included in the selected model. Hence, glycemic control and 
albuminuria were important factors in predicting serum uric acid.  
The three final models all contained HbA1c and central obesity. HbA1c was correlated 
with three novel biomarkers. HbA1c measures the level of glycemic control and existence of 
HbA1c in the final three models indicate the close relationships between glycemic control and 
potential biomarkers. Central obesity was measured by waist/height ratio and it was highly 
related to the three novel biomarkers. Moreover, serum-related variables such as cholesterol, 
Creatinine, HDL and Triglycerides were considered important in predicting the three biomarkers. 
ACR, which measures the albuminuria, the current gold standard for predicting the progression 
of diabetic nephropathy, was an important predictor for eGFR and serum uric acid models.  
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Table 24 shows the results for the different model selection criteria of the three models.  
Log (eGFR) model is the most predictive model among the three because it had the highest R-
square, which was larger than 0.5. Also, the log (eGFR) model had the lowest AIC, BIC, 
Mallow’s Cp, and CV PRESS, which demonstrated that log (eGFR) model was relatively a 
precise model of predicting the dependent variable and estimating parameters. For the other two 
models, log (α-klotho) model had the lowest R-square, highest AIC, BIC, and CV PRESS among 
the three models, which indicated that α-klotho model was the least predictive model.  
For all three models, the R-square was not that large. The largest R-square was 0.62, 
which indicated that there was still 38% of variance could not explained by selected variables. In 
addition, the Mallow’s Cp of three models were all smaller than the number of predictors plus 1, 
which indicate a tendency of overfitting. By looking at the database, the sample size of all three 
models were less than 70 and there were more than 15 variables in the maximum model. Thus, 
overfitting issues could exist in the selection of the final models. In the future studies, more 
children should be recruited to increase the sample size and avoid overfitting issues. More 
clinical predictors could be measured and added to the study to derive more predictive models 
with higher R-square. Longitudinal analysis with follow-up data are needed to test the time trend 
and whether other time-dependent models are more appropriate, such as linear mixed model and 
GEE. 
For the ACR model with three potential risk biomarkers and other variables, after model 
selection, none of three biomarkers (α-klotho, eGFR and serum uric acid) were considered 
important predictors of ACR. SBP percentile, DBP percentile, HDL and Triglycerides were 
important predictors for predicting ACR. However, the R-square of the model was relatively low 
(0.275) and CV PRESS was larger than 50, which indicated that this ACR model was not an 
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accurate model and was not predictive for new observations. Due to the small sample size and 
restricted numbers of variables, this ACR model may not reflect the true relationship between 
ACR and three potential biomarkers. In the future study, more children should be recruited to 
increase the sample size. In addition, more variables with fewer missing data need to be 
considered in order to elevate the R-square. Moreover, follow-up data should be collected and 
longitudinal analysis need to be performed to assess the relationship between ACR and potential 
biomarkers. 
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APPENDIX A: SUPPLEMENTAL RESULTS 
Table 27. Characteristics of children with diabetic nephropathy by ACR normal and abnormal groups 
Variable 
ACR normal group 
(ACR < 30 mg/g) 
(n = 74) 
ACR abnormal 
group 
(ACR ≥ 30 mg/g) 
(n=15) 
p-value 
Sex (Male)  5 (33.3) 0.10 
  Male 42 (56.8) 5 (33.3)  
  Female 32 (43.2)   
Race (White) 66 (89.2) 13 (86.7) 0.63 
Age (years) 16.1 ± 3.0 15.3 ± 2.7 0.35  
Diabetes duration (years) 7.1 ± 3.6 7.6 ± 4.8 0.65 
Average SBP (mm Hg) 114.3 ± 8.3 111.5 ± 7.4 0.23  
Average DBP (mm Hg) 72.5 ± 5.1 70.1 ± 7.1 0.33 
BMI (kg/m2) 23.7 ± 4.8 22.7 ± 6.1 0.49  
Waist circumference (cm) 81.0 ± 12.0 72.0 ± 12.5 0.02  
Waist/height ratio 0.49 ± 0.06 0.45 ± 0.08 0.07  
Growth velocity (cm/year) 2.6 ± 2.7 3.6 ± 2.9 0.20  
Hemoglobin A1c (%) 8.0 ± 1.3 8.5 ± 1.4 0.15  
Insulin dose (u/kg/d) 0.88 ± 0.26 0.93 ± 0.26 0.66  
α-klotho (pg/mL) 1270.4 ± 540.5 1387.6 ± 648.3 0.37  
Cystatin C (mg/L) 0.83 ± 0.14 0.77 ± 0.12 0.16 
Estimated GFR 
(ml/kg/1.73m2) 
97.56 ± 19.81 105.50 ± 19.31 0.16  
Serum Uric Acid (mg/dL) 3.83 ± 0.98 3.57 ± 0.92 0.34 
Creatinine (mg/dL) 1.95 ± 10.76 0.69 ± 0.15 0.15  
Triglycerides (mg/dL) 98.2 ± 61.33 126.0 ± 109.4 0.34  
Total cholesterol (mg/dL) 164.9 ± 26.89 176.7 ± 30.5 0.13  
LDL (mg/dL) 90.0 ± 24.67 96.6 ± 20.7 0.34  
HDL (mg/dL) 56.3 ±  60.9 ± 9.7 0.15  
Mann-Whitney U test or Students’ t-test for continuous variables and Fisher’s exact test or chi-square 
test for categorical variables. 
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Table 28. Characteristics of children with diabetic nephropathy by ACR quartiles 
Variable 
1st ACR 
quartile 
(n=21) 
2nd ACR 
quartile 
(n=23) 
3rd ACR 
quartile 
(n=23) 
4th ACR 
quartile 
(n=22) 
Sex (Male) 14 (66.6) 10 (43.5) 12 (52.2) 11 (50.0) 
Race (White) 20 (95.2) 20 (87.0) 21 (91.3) 18 (81.8) 
Age (years) 16.2 ± 2.0 15.7 ± 3.2 16.3 ± 3.1 15.7 ± 3.2 
Diabetes duration (years) 7.2 ± 3.6 7.0 ± 3.5 7.1 ± 4.2 7.4 ± 4.1 
Average SBP (mm Hg) 111.0 ± 7.7 115.0 ± 8.6 116.5 ± 8.7 112.5 ± 7.1 
Average DBP (mm Hg) 70.7 ± 5.2 73.8 ± 4.5 72.8 ± 5.5 71.4 ± 6.4 
Height (cm) 167.7 ± 13.6 163.6 ± 10.9 161.8 ± 11.1 162.0 ± 14.1 
Weight (kg) 67.6 ± 19.1 66.4 ± 19.8 62.5 ± 18.4 57.6 ± 18.3 
BMI (kg/m2) 24.0 ± 4.3 24.3 ± 5.2 23.4 ± 4.6 22.4 ± 5.9 
Waist circumference (cm)a 81.9 ± 10.3 83.2 ± 12.3 78.3 ± 12.4 74.6 ± 14.1 
WHR 0.48 ± 0.05 0.51 ± 0.07 0.48 ± 0.05 0.46 ± 0.08 
Growth velocity (cm/year) 2.1 ± 2.1 2.8 ± 3.3 3.0 ± 2.7 3.3 ± 2.8 
Hemoglobin A1c (%) 7.8 ± 1.3 8.0 ± 1.3 8.1 ± 1.3 8.3 ± 1.4 
Insulin dose (u/kg/d) 0.87 ± 0.30 0.97 ± 0.28 0.85 ± 0.22 0.87 ± 0.23 
α-klotho (pg/mL) 1197.1 ± 315.3 1380.1 ± 651.1 1292.7 ± 637.6 1293.0 ± 584.6 
Cystatin C (mg/L)a 0.89 ± 0.13 0.80 ± 0.15 0.80 ± 0.15 0.79 ± 0.11 
Estimated GFR 
(ml/kg/1.73m2) 89.47 ± 14.33 103.43 ± 25.16 100.87 ± 18.97 102.85 ± 18.23 
Serum Uric Acid (mg/dL) 3.88 ± 1.09 3.79 ± 0.77 3.84 ± 0.90 3.65 ± 1.14 
Creatinine (mg/dL) 0.70 ± 0.15 0.68 ± 0.15 4.60 ± 18.90 0.69 ± 0.17 
Triglycerides (mg/dL) 82.6 ± 43.0 119.7 ± 87.1 98.4 ± 46.3 109.2 ± 93.6 
Total cholesterol (mg/dL) 166.5 ± 19.7 169.6 ± 26.2 159.8 ± 34.1 172.0 ± 28.8 
LDL (mg/dL) 89.1 ± 27.1 97.3 ± 21.6 85.0 ± 27.0 93.1 ± 19.5 
HDL (mg/dL) 56.8 ± 10.2 53.6 ± 10.2 57.1 ± 13.4 60.9 ± 10.9 
a Significant linear trend, p < 0.05 
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Table 29. Characteristics of children with diabetic nephropathy by low HbA1c and high HbA1c groups 
Variable 
Low HbA1c group 
(HbA1c <7.5%) 
(n=32) 
High HbA1c group 
(HbA1c ≥7.5%) 
(n=66) 
p-value 
Sex (Male) 18 (56.3) 32 (48.5) 0.47 
Race (White) 30 (96.8) 57 (87.7) 0.26 
Age (years) 16.6 ± 3.2 15.4 ± 2.7 0.04  
Diabetes duration (years) 6.3 ± 4.4 7.4 ± 3.5 0.06  
Average SBP (mm Hg) 114.9 ± 7.3 112.8 ± 8.9 0.26  
Average DBP (mm Hg) 72.7 ± 4.5 71.6 ± 6.0 0.40  
Height (cm) 166.8 ± 11.3 161.4 ± 12.8 0.04  
Weight (kg) 64.4 ± 15.0 62.0 ± 20.5 0.29  
BMI (kg/m2) 23.1 ± 4.1 23.5 ± 5.3 0.74  
Waist circumference (cm) 79.9 ± 9.1 78.5 ± 13.6 0.58 
WHR 0.48 ± 0.05 0.48 ± 0.07 0.98  
Growth velocity (cm/year) 2.5 ± 2.5 3.0 ± 2.8 0.58  
ACR (mg/g) 12.7 ± 14.4 27.2 ± 70.4 0.20  
Insulin dose (u/kg/d) 0.81 ± 0.25 0.94 ± 0.26 0.03  
Soluble α-klotho (pg/mL) 1485.8 ± 628.3 1216.7 ± 517.0 0.03 
Cystatin C (mg/L) 0.85 ± 0.16 0.79 ± 0.12 0.05  
Estimated GFR 
(ml/kg/1.73m2) 
94.11 ± 18.44 103.02 ± 21.29 0.07  
Serum Uric Acid (mg/dL) 4.28 ± 0.99 3.55 ± 0.83 0.0003  
Creatinine (mg/dL) 3.64 ± 16.27 0.66 ± 0.13 0.04  
Triglycerides (mg/dL) 88.6 ± 47.0 109.5 ± 77.6 0.16  
Total cholesterol (mg/dL) 162.5 ± 21.1 167.7 ± 29.8 0.32 
LDL (mg/dL) 90.6 ± 19.4 90.1 ± 25.8 0.93  
HDL (mg/dL) 54.8 ± 11.3 58.1 ± 11.7 0.19  
Mann-Whitney U test or Students’ t-test for continuous variables and Fisher’s exact test or chi-square test 
for categorical variables. 
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Table 30. Correlations between Hemoglobin A1c and physical characteristics, glycemic control,  
urine-related, serum related variables adjusting for age (Spearman correlation) 
 
Variables Adjusted r p-value 
Diabetes duration (years) 0.26 0.01 
Average SBP (mm Hg) -0.02 0.83 
Average DBP (mm Hg) 0.11 0.28 
Height (cm) -0.06 0.58 
Weight (kg) -0.04 0.69 
BMI (kg/m2) 0.02 0.86 
Waist circumference (cm) 0.03 0.80 
WHR 0.07 0.54 
Growth velocity (cm/year) -0.11 0.30 
ACR (mg/g) 0.16 0.15 
Insulin dose (u/kg/d) 0.25 0.03 
Soluble α-klotho (pg/mL) -0.32 0.004 
Serum Uric Acid (mg/dL) -0.22 0.04 
Cystatin C (mg/L) -0.20 0.06 
Estimated GFR 
(ml/kg/1.73m2) 
0.21 0.06 
Creatinine (mg/dL) -0.21 0.05 
Triglycerides (mg/dL) 0.31 0.002 
Total cholesterol (mg/dL) 0.09 0.38 
LDL (mg/dL) 0.004 0.97 
HDL (mg/dL) 0.09 0.38 
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Table 31. Correlations between ACR and physical characteristics, glycemic control, urine-related, 
serum related variables adjusting for age (Spearman correlation) 
 
Variables Adjusted r p-value 
Diabetes duration (years) -0.004 0.97 
Average SBP (mm Hg) 0.17 0.10 
Average DBP (mm Hg) 0.07 0.50 
Height (cm) -0.13 0.24 
Weight (kg) -0.18 0.09 
BMI (kg/m2) -0.17 0.11 
Waist circumference (cm) -0.28 0.02 
WHR -0.27 0.03 
Growth velocity (cm/year) 0.17 0.12 
Hemoglobin A1c (%) 0.16 0.15 
Insulin dose (u/kg/d) -0.03 0.80 
Soluble α-klotho (pg/mL) 0.02 0.84 
Serum Uric Acid (mg/dL) -0.04 0.74 
Cystatin C (mg/L) -0.21 0.06 
Estimated GFR 
(ml/kg/1.73m2) 
0.21 0.06 
Creatinine (mg/dL) 0.04 0.69 
Triglycerides (mg/dL) 0.12 0.26 
Total cholesterol (mg/dL) 0.05 0.65 
LDL (mg/dL) -0.03 0.80 
HDL (mg/dL) 0.16 0.14 
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Table 32. Correlations between estimated GFR and physical characteristics, other potential 
biomarkers adjusting for age (Spearman correlation) 
 
Variables Adjusted r p-value 
Diabetes duration (years) -0.17 0.13 
Average SBP (mm Hg) 0.10 0.37 
Average DBP (mm Hg) 0.23 0.03 
Height (cm) -0.37 0.0005 
Weight (kg) -0.11 0.30 
BMI (kg/m2) 0.10 0.34 
Waist circumference (cm) 0.11 0.40 
WHR 0.33 0.007 
Growth velocity (cm/year) -0.32 0.003 
Soluble α-klotho (pg/mL) -0.19 0.11 
Serum Uric Acid (mg/dL) -0.36 0.0007 
 
 
Figure 12. Fit criteria for the best selected log (α-klotho) model 
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Table 33. Model selection criteria with or without central obesity and waist% for eGFR model 
 N R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
With central 
obesity and 
waist% 
52 0.6176 0.5568 -140.23 -185.62 0.18 1.24 
Without central 
obesity and 
waist% 
70 0.2700 0.2005 -165.25 -232.98 4.03 2.35 
 
Table 34. Model selection criteria without central obesity and waist% for non-missing dataset for eGFR 
model 
 
 N R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
Without central 
obesity and 
waist% for non-
missing dataset 
52 0.5744 0.5176 -136.66 -183.83 0.14 1.32 
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Figure 13. Fit criteria for the best selected log (eGFR) model 
 
Table 35. Model selection criteria with or without central obesity and waist% for serum uric acid model 
 N R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
With central 
obesity and 
waist% 
54 0.4467 0.3181 -91.75 -138.40 8.15 3.48 
Without central 
obesity and 
waist% 
75 0.2075 0.1740 -137.22 -211.35 0.41 4.36 
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Table 36. Model selection criteria without central obesity and waist% for non-missing dataset for serum 
uric acid model 
 
 N R2 Adjusted R2 AIC BIC Mallow’s Cp CV PRESS 
Without central 
obesity and 
waist% for non-
missing dataset 
54 0.3447 0.2765 -92.62 -144.10 2.37 3.45 
 
 
Figure 14. Fit criteria for the best selected log (serum uric acid) model 
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Figure 15. Regression diagnostics for log (α-klotho) model 
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Figure 16. Residual analysis for log (α-klotho) model 
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Figure 17. Regression diagnostics for log (eGFR) model 
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Figure 18. Residual analysis for log (eGFR) model 
 
 77 
 
Figure 19. Regression diagnostics for log (serum uric acid) model 
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Figure 20. Residual analysis for log (serum uric acid) model 
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Figure 21. Fit criteria for the log (ACR) model with biomarkers and other variables 
 
Table 37. VIF of log (ACR) model with biomarkers and other variables 
 HbA1c Diabetic duration Age SBP% DBP% TG HDL 
VIF 1.20 1.24 1.13 1.84 1.88 1.16 1.07 
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Figure 22. Scatter plot of residuals by predicted values for log (ACR) model 
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Figure 23. QQ plot of residuals for log (ACR) model 
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Figure 24. Plots of problematic points for log (ACR) model 
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Figure 25. Regression diagnostics for log (ACR) model 
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Figure 26. Residual analysis for log (ACR) model 
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APPENDIX B: RELEVANT SAS CODES 
 
 
LIBNAME results 'C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing'; 
LIBNAME DN 'C:\Users\fuhaoyi\Desktop\study\thesis\2017 Spring'; 
 
PROC FORMAT; 
  VALUE include 1='Yes' 0='No'; 
  VALUE gender 1='Male' 2='Female'; 
  VALUE racegroup 1='White' 2='AA' 3='Asian' 4='Hispanic' 5='Other'; 
  VALUE insulin 1='MDI' 2='CSII' 3='Pre-mixed'; 
  VALUE rscreen 1='CHP' 2='OSH'; 
  VALUE rstatus 0='Neg' 1='NP' 2='P'; 
  VALUE medi 0='None' 1='ACE' 2='Other Antihypertensive' 3='Metformin' 
4='OCP' 5='Statin'; 
  VALUE diabN 1='NA' 2='IMA' 3='PMA' 4='MA'; 
  VALUE diabyrs 0-<5 = '<5' 5-high = '>=5'; 
  VALUE tanner 1='pre-pubertal' 2-3 = 'early-pubertal' 4-5 = 'late-pubertal'; 
  VALUE bmi 0-<85 = 'normal' 85-<95 = 'overweight' 95-high = 'obese'; 
  VALUE bmi2gp 0-<85 = 'normal' 85-high = 'abnormal'; 
  VALUE ratio 0-<0.5 = 'No' 0.5-high = 'Yes'; 
  VALUE growth 0-<5 = 'slow' 5-high = 'fast'; 
  VALUE A1cPOC 0-<7.5 = '<7.5' 7.5-high = '>=7.5'; 
  VALUE ACR1gp 0-<30 = 'Normal' 30-<300 = 'micro albuminuria' 300-high = 
'macro albuminuria'; 
  VALUE ACR2gp 0-<30 = 'Normal' 30-high = 'Abnormal'; 
  VALUE AER 0-<30 = 'Normal' 30-<300 = 'micro albuminuria' 300-high = 'macro 
albuminuria'; 
  VALUE quartiles 0 = '1' 1 = '2' 2 = '3' 3 = '4'; 
  VALUE race2gp 1 = 'White' 2 = 'AA'; 
  VALUE lwc_perc 0='0 %ile' 1='10 %ile' 2='25 %ile' 3='50 %ile' 4='75 %ile' 
5='85 %ile' 6='90 %ile' ; 
  VALUE LB_SEX 1=Female 2=Male; 
  
RUN; 
 
data thesis_results; 
  set DN.pedrodata_haoyi_2017_03_11; 
run; 
 
DATA final_analysis; 
  SET thesis_results(keep= mrn AgeCollection DiabDur p_sbp_score p_dbp_score 
new_BMIPCT whratio GrowthVel meanA1c ACR  
      aklothoSol eGFR SerumUricAcid Creat TG TotalChol LDL HDL sex race 
CentralObesity wc_perc A1cPOCgp ACR2gpd); 
RUN; 
     
DATA final_analysis; 
  SET final_analysis; 
    logeGFR=log(eGFR); 
 logak=log(aklothoSol); 
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 logsua=log(SerumUricAcid); 
RUN; 
 
DATA final_analysis; 
  SET final_analysis; 
  IF ACR ne 536.2; 
RUN; 
 
data final_analysis; 
  set final_analysis; 
    if A1cPOCgp = <7.5 then A1cPOC2gp=0; 
    if A1cPOCgp > 7.5 then A1cPOC2gp=1; 
 if -888<ACR<30 then ACR2gpd2=0; 
 if ACR>=30 then ACR2gpd2=1; 
 if MISSING(ACR) then ACR2gpd2=.; 
 sex2 = sex -1; 
 if race =1 then race2=1; 
 else if race =2 then race2=0; 
 else if race=3 or race =4 or race=5 then race2=.; 
 if .<whratio<0.5 then co=0; 
 if whratio>=0.5 then co=1; 
 if missing(whratio) then co=.; 
run; 
 
/* table 1 */ 
ODS RTF FILE='C:\Users\fuhaoyi\Desktop\study\thesis\thesis 
writing\descriptive.rtf'STYLE=journal; 
PROC MEANS DATA=final_analysis MAXDEC=2 N MEAN STDDEV P25 MEDIAN P75 MIN MAX; 
  VAR AgeCollection DiabDur p_sbp_score p_dbp_score new_BMIPCT whratio 
GrowthVel meanA1c ACR  
      aklothoSol eGFR SerumUricAcid Creat TG TotalChol LDL HDL; 
RUN; 
 
/* table 2 */ 
PROC FREQ DATA=final_analysis; 
  TABLES sex race CentralObesity wc_perc A1cPOCgp ACR2gpd; 
RUN; 
 
ODS RTF CLOSE; 
 
%macro table3(varname1, varname2, name); 
   ods output spearmancorr=&name; 
   proc corr data=final_analysis spearman; 
     with &varname1; 
  var &varname2; 
   run; 
 
   data &name; 
     set &name; 
     format _numeric_ 5.2; 
   run; 
 
   ods rtf file= 'C:\Users\fuhaoyi\Desktop\study\thesis\thesis 
writing\correlation.rtf'; 
   proc print data=&name; 
   run; 
   ods rtf close; 
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%mend; 
 
/* Table 3 Correlations between alpha-klotho and other independent variables 
*/ 
%table3 (AgeCollection DiabDur p_sbp_score p_dbp_score new_BMIPCT whratio 
GrowthVel meanA1c ACR  
          Creat TG TotalChol LDL HDL,aklothoSol, correlation_ak); 
 
/* Table 4 Correlations between eGFR and other independent variables */ 
%table3 (AgeCollection DiabDur p_sbp_score p_dbp_score new_BMIPCT whratio 
GrowthVel meanA1c ACR  
          Creat TG TotalChol LDL HDL, eGFR, correlation_eGFR); 
 
/* Table 5 Correlations between serum uric acid and other independent 
variables */ 
%table3 (AgeCollection DiabDur p_sbp_score p_dbp_score new_BMIPCT whratio 
GrowthVel meanA1c ACR  
          Creat TG TotalChol LDL HDL,SerumUricAcid, correlation_sua); 
 
PROC CORR DATA=final_analysis; 
  VAR AgeCollection DiabDur p_sbp_score p_dbp_score new_BMIPCT whratio 
GrowthVel meanA1c ACR  
          Creat TG TotalChol LDL HDL; 
RUN; 
 
%macro uniak(varname1); 
   proc reg data=final_analysis plots=none; 
     model logak=&varname1; 
   run; 
%mend; 
 
/*Table 6. Univariable regression models for log a-klotho */ 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing\uniak.rtf'; 
%uniak (AgeCollection); %uniak (DiabDur);  %uniak (p_sbp_score);  %uniak 
(p_dbp_score); %uniak (new_BMIPCT);  
%uniak (whratio); %uniak (GrowthVel);  %uniak (meanA1c); %uniak (ACR); %uniak 
(Creat);  
%uniak (TG); %uniak (TotalChol); %uniak (LDL); %unieGFR (HDL); %uniak (sex2); 
%uniak (race2); %uniak (co); %uniak (wc_perc); %uniak (A1cPOC2gp); %uniak 
(ACR2gpd2); 
ods rtf close; 
 
%macro unieGFR(varname1); 
   proc reg data=final_analysis plots=none; 
     model logeGFR=&varname1; 
   run; 
%mend; 
 
/* Table 7. Univariable regression models for logeGFR */ 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis 
writing\unieGFR.rtf'; 
%unieGFR (AgeCollection); %unieGFR (DiabDur);  %unieGFR 
(p_sbp_score);  %unieGFR (p_dbp_score); %unieGFR (new_BMIPCT);  
%unieGFR (whratio); %unieGFR (GrowthVel);  %unieGFR (meanA1c); %unieGFR 
(ACR); %unieGFR (Creat);  
%unieGFR (TG); %unieGFR (TotalChol); %unieGFR (LDL); %unieGFR (HDL); %unieGFR 
(sex2); 
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%unieGFR (race2); %unieGFR (co); %unieGFR (wc_perc); %unieGFR 
(A1cPOC2gp); %unieGFR (ACR2gpd2); 
ods rtf close; 
 
%macro unisua(varname1); 
   proc reg data=final_analysis plots=none; 
     model logsua=&varname1; 
   run; 
%mend; 
 
/* Table 8. Univariable regression models for log serum uric acid */ 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis 
writing\unisua.rtf'; 
%unisua (AgeCollection); %unisua (DiabDur);  %unisua (p_sbp_score);  %unisua 
(p_dbp_score); %unisua (new_BMIPCT);  
%unisua (whratio); %unisua (GrowthVel);  %unisua (meanA1c); %unisua 
(ACR); %unisua (Creat);  
%unisua (TG); %unisua (TotalChol); %unisua (LDL); %unisua (HDL); %unisua 
(sex2); 
%unisua (race2); %unisua (co); %unisua (wc_perc); %unisua 
(A1cPOC2gp); %unisua (ACR2gpd2); 
ods rtf close; 
 
PROC CORR DATA=final_analysis; 
  VAR AgeCollection DiabDur p_sbp_score p_dbp_score new_BMIPCT whratio 
GrowthVel meanA1c ACR  
          Creat TG TotalChol LDL HDL; 
RUN; 
 
/* Table 9. Selected variables for different model selection criteria and k-
fold cross-validation for log(alpha-klotho) */ 
proc reg data=final_analysis; 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward 
slstay=0.2; 
run; 
 
data final_analysis2; 
  set final_analysis; 
  if centralobesity ne .; 
run; 
 
data final_analysis2; 
  set final_analysis2; 
  if wc_perc ne .; 
run; 
 
/* log(alpha-klotho) model with centralobesity and waist% */  
/* no cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=press)  
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cvMethod=split(2) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 2-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(2) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 5-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(5) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 10-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(10) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* n-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(45) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* log(alpha-klotho) model without centralobesity and waist% */  
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 /selection=backward (choose=BIC 
select=cv)  
cvMethod=split(66) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* log(alpha-klotho) model without centralobesity and waist% excluded missing 
data */  
proc glmselect data=final_analysis2 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
 90 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 /selection=backward (choose=BIC 
select=cv)  
cvMethod=split(45) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* n-fold cross-validation */ 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing\ak fit 
stat.rtf'; 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logak=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(45) stats=all cvdetails=cvpress SHOWPVALS; 
run; 
ods rtf close; 
 
 
/* log(eGFR) model with central obesity and waist percentile*/ 
/* no cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=press)  
cvMethod=split(2) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 2-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(2) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 5-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(5) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 10-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
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          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(10) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* n-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(52) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* log(eGFR) model without centralobesity and waist% */  
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2/selection=backward (choose=BIC 
select=cv)  
cvMethod=split(70) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* log(eGFR) model without centralobesity and waist% excluded missing data */  
proc glmselect data=final_analysis2 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2/selection=backward (choose=BIC 
select=cv)  
cvMethod=split(52) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* n-fold cross-validation */ 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing\eGFR fit 
stat.rtf'; 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logeGFR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score 
new_BMIPCT GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(52) stats=all cvdetails=cvpress SHOWPVALS; 
run; 
ods rtf close; 
 
/* log(serum uric acid) model with central obesity and waist percentile*/ 
/* no cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity wc_perc 
/selection=backward (choose=BIC select=press)  
cvMethod=split(2) stats=all cvdetails=cvpress SHOWPVALS details=all; 
 92 
run; 
 
/* 2-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(2) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 5-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(5) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* 10-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(10) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* n-fold cross-validation */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(54) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* log(serum uric acid) model without centralobesity and waist% */  
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 /selection=backward (choose=BIC 
select=cv)  
cvMethod=split(75) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* log(serum uric acid) model without centralobesity and waist% excluded 
missing data */  
proc glmselect data=final_analysis2 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
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model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 /selection=backward (choose=BIC 
select=cv)  
cvMethod=split(54) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* n-fold cross-validation */ 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing\sua fit 
stat.rtf'; 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logsua=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score new_BMIPCT 
GrowthVel ACR   
          Creat TG TotalChol HDL sex2 race2 centralobesity 
wc_perc/selection=backward (choose=BIC select=cv)  
cvMethod=split(54) stats=all cvdetails=cvpress SHOWPVALS; 
run; 
ods rtf close; 
 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing\vif.rtf'; 
/* vif checking for logak */ 
proc reg data=final_analysis; 
  model logak=meanA1c growthVel TG ACR TotalChol HDL Centralobesity wc_perc / 
vif; 
run; 
 
/* vif checking for logeGFR */ 
proc reg data=final_analysis; 
  model logeGFR=meanA1c p_dbp_score growthVel ACR Creat TotalChol 
Centralobesity / vif; 
run; 
 
/* vif checking for logsua */ 
proc reg data=final_analysis; 
  model logsua=meanA1c DiabDur AgeCollection ACR Creat TG TotalChol HDL 
Centralobesity wc_perc/ vif; 
run; 
ods rtf close; 
 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis 
writing\assumption.rtf'; 
/* linearity checking for logak */ 
proc reg data=final_analysis 
  plots=(RESIDUALBYPREDICTED); 
  model logak=meanA1c growthVel TG ACR TotalChol HDL Centralobesity wc_perc; 
run; 
 
/* linearity checking for logeGFR */ 
proc reg data=final_analysis 
  plots=(RESIDUALBYPREDICTED); 
  model logeGFR=meanA1c p_dbp_score growthVel ACR Creat TotalChol 
Centralobesity; 
run; 
 
/* linearity checking for logsua */ 
proc reg data=final_analysis 
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  plots=(RESIDUALBYPREDICTED); 
  model logsua=meanA1c DiabDur AgeCollection ACR Creat TG TotalChol HDL 
Centralobesity wc_perc; 
run; 
 
/* Normality checking for logak */ 
proc reg data=final_analysis 
  plots=(QQPLOT); 
  model logak=meanA1c growthVel TG ACR TotalChol HDL Centralobesity wc_perc; 
run; 
 
/* Normality checking for logeGFR */ 
proc reg data=final_analysis 
  plots=(QQPLOT); 
  model logeGFR=meanA1c p_dbp_score growthVel ACR Creat TotalChol 
Centralobesity; 
run; 
 
/* Normality checking for logsua */ 
proc reg data=final_analysis 
  plots=(QQPLOT); 
  model logsua=meanA1c DiabDur AgeCollection ACR Creat TG TotalChol HDL 
Centralobesity wc_perc; 
run; 
ods rtf close; 
 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis 
writing\problematic points.rtf '; 
/* Problematic points for logak */ 
proc reg data=final_analysis 
plots=(RStudentByLeverage(label) CooksD(label) DFFITS(label)); 
model logak=meanA1c growthVel TG ACR TotalChol HDL Centralobesity wc_perc; 
run; 
ods rtf close; 
 
/* Problematic points for logeGFR */ 
proc reg data=final_analysis 
plots=(RStudentByLeverage(label) CooksD(label) DFFITS(label)); 
model logeGFR=meanA1c p_dbp_score growthVel ACR Creat TotalChol 
Centralobesity; 
run; 
 
/* Problematic points for logsua */ 
proc reg data=final_analysis 
plots=(RStudentByLeverage(label) CooksD(label) DFFITS(label)); 
model logsua=meanA1c DiabDur AgeCollection ACR Creat TG TotalChol HDL 
Centralobesity wc_perc; 
run; 
ods rtf close; 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing\ACR.rtf'; 
/* ACR normality check */ 
proc univariate data=final_analysis; 
  var ACR; 
  histogram ACR / normal; 
run; 
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/* logACR */ 
data final_analysis; 
  set final_analysis; 
  logACR=log(ACR); 
run; 
 
/* log(ACR) normality check */ 
proc univariate data=final_analysis; 
  var logACR; 
  histogram logACR / normal; 
run; 
 
/* logACR model with three biomarkers */ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logACR=meanA1c DiabDur AgeCollection aklothoSol eGFR SerumUricAcid 
/selection=backward (choose=BIC select=cv include=3)  
cvMethod=split(66) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* logACR model with three biomarkers and other variables*/ 
proc glmselect data=final_analysis 
plots(stepAxis=number)=(criterionPanel ASEPlot); 
model logACR=meanA1c DiabDur AgeCollection aklothoSol eGFR SerumUricAcid  
             p_sbp_score p_dbp_score TG HDL LDL/selection=backward 
(choose=BIC select=cv include=3)  
cvMethod=split(61) stats=all cvdetails=cvpress SHOWPVALS details=all; 
run; 
 
/* vif checking for logACR */ 
proc reg data=final_analysis; 
  model logACR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score TG HDL / 
vif; 
run; 
 
/* linearity checking for logACR */ 
proc reg data=final_analysis 
  plots=(RESIDUALBYPREDICTED); 
  model logACR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score TG HDL; 
run; 
 
/* Normality checking for logACR */ 
proc reg data=final_analysis 
  plots=(QQPLOT); 
  model logACR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score TG HDL; 
run; 
ods rtf file='C:\Users\fuhaoyi\Desktop\study\thesis\thesis writing\ACR.rtf'; 
/* Problematic points for logACR */ 
proc reg data=final_analysis 
plots=(RStudentByLeverage(label) CooksD(label) DFFITS(label)); 
model logACR=meanA1c DiabDur AgeCollection p_sbp_score p_dbp_score TG HDL; 
run; 
ods rtf close; 
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